Transcriptional regulators of TEAD family
Through the analysis of TEAD-500 gene list and discriminant function, the difficulties of TEAD complex activity measurement and treatment response prediction were solved, and the accurate evaluation of TEAD complex activity and prediction of treatment response were achieved, which improved the effectiveness of tumor treatment and drug resistance. sex monitoring.
Patent Information
- Application Number
- CN202380029456.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-23
- Filing Date
- 2023-03-22
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art is difficult to effectively measure and evaluate the activity of TEAD complexes in cancer and their prediction of their response to treatment, resulting in the failure to effectively monitor and prevent tumor development and therapeutic resistance.
By identifying and using gene expression differences in the TEAD-500 gene list, transcription tags were developed to evaluate the activity of TEAD complexes and, in combination with discriminant function analysis, gene tags were developed to predict cancer type and treatment response.
A robust measurement of TEAD complex activity and accurate classification of tumor types were achieved, predicted treatment response and survival, and improved the accuracy of pharmacodynamic evaluation and clinical trials of TEAD pathway inhibitors.
Smart Images

Figure BDA0005054562520000101 
Figure BDA0005054562520000111 
Figure BDA0005054562520000121
Abstract
Description
Background Art
[0001] In normal tissues, the transcriptional cofactors YAP1 and WWTR1 bind to the transcription factors (TEAD1, TEAD2, TEAD3, and TEAD4) of the TEAD family, collectively referred to as "TEAD", to form an active protein complex. This complex recognizes and binds to specific sequence motifs in the promoter of target genes and activates or inhibits the transcription of the target genes. Therefore, TEAD can regulate cell proliferation, survival, adaptation, and migration that are necessary for normal biological processes such as organ growth and wound healing (Totaro A et al. Nat Cell Biol. 2018; 20(8): 888-899. doi: 10.1038 / s41556-018-0142-z). In intact adult mammalian tissues, YAP1 and WWTR1 are usually phosphorylated by the kinases of the Hippo pathway, thereby being retained in the cytoplasm and degraded. In this case, there is no active transcription complex in the nucleus (Totaro A et al. Nat Cell Biol 2018 August; 20(8): 888-899).
[0002] Over the past few years, YAP1, WWTR1, their TEAD partners, and their upstream regulators—particularly the tumor suppressor pathway known as the Hippo pathway—have gained increasing attention in cancer research (Zhang N et al. Dev Cell. 2010 Jul 20;19(1):27-38. doi:10.1016 / j.devcel.2010.06.015; Lu L et al. Proc Natl Acad Sci US A. 2010;107(4):1437-42. doi:10.1073 / pnas.0911427107; Nishio M et al. Proc Natl Acad Sci US A. 2016;113(1):E71-80. doi:10.1073 / pnas.1517188113; Liu-Chittenden Y et al. Genes Rev. 2016;114(1):E71-80. doi:10.1073 / pnas.1517188113). Dev. 2012; 26(12): 1300-5. doi: 10.1101 / gad.192856.112). Mutations or physiological disorders of YAP1, WWTR1, or any of their upstream regulators may lead to insufficient phosphorylation and degradation of these proteins. In the absence of phosphorylation and degradation, transcriptional cofactors enter the nucleus, bind to TEAD, and activate oncogenic transcription. Increased activity of any component of the complex may increase or decrease transcription of downstream effectors (TEAD-dependent transcription). Some regulated genes are direct targets of TEADs with TEAD binding motifs (Zanconato, F. et al. Nat Cell Biol 2015: 17: 1218-1227). Other regulated genes are indirectly regulated. Therefore, the Hippo-YAP1 / WWTR1-TEAD pathway (hereinafter referred to as the "TEAD pathway") may directly trigger tumorigenesis or render existing tumors resistant to targeted therapies (Reggiani F et al. Biochim Biophys Acta Rev Cancer. 2020: 1873(1): 188341. doi: 10.1016 / j.bbcan.2020.188341; Kurppa KJ et al. Cancer Cell. 2020; 37(1): 104-122.e12. doi: 10.1016 / j.ccell.2019.12.006).
[0003] For example, mutations and deletions of Hippo genes such as LATS2 and NF2 account for a large proportion of malignant mesothelioma tumors (Sekido Y et al. Cancers (Basel). 2018; 10(4): 90. doi: 10.3390 / cancers10040090). YAP1 was found to be locally amplified and overexpressed at both the RNA and protein levels in several types of tumors, especially in cervical cancer (Zanconato F et al. Cancer Cell. 2016; 29(6): 783-803. doi: 10.1016 / j.ccell.2016.05.005). Activation of TEAD-dependent transcription may endow tumor cells with a mesenchymal stem cell-like phenotype, since well-known stem cell transcription factors like SOX2, OCT3 / 4, NANOG, and MYC are also controlled by TEAD (Bora-Singhal N et al. Stem Cells. 2015; 33(6): 1705-18. doi: 10.1002 / stem.1993).
[0004] To measure the transcriptional activity of such complexes, estimate the proportion of cases in which TEAD-dependent transcription may lead to tumor development or progression, and evaluate the target engagement and pharmacodynamics of novel TEAD pathway inhibitors, we have identified a universal transcriptional signature and several tissue-specific transcriptional signatures that include genes that are upregulated (positive effectors) or downregulated (negative effectors) when the YAP1 / WWTR1-TEAD complex ("TEAD complex") is activated. Conversely, when the complex is inhibited, positive effectors are downregulated and negative effectors are upregulated.
[0005] The universal signature referred to herein as the "TEAD-500" gene list is derived from the top 500 differentially expressed genes, which have approximately equal proportions of positive and negative downstream effectors. More specifically, the TEAD-500 gene list includes about 90% of these genes down from 482 genes. The universal signature is robustly applicable to all types of cancer. It robustly measures TEAD activity, classifies samples, and predicts their response to TEAD pathway regulation. TEAD-500 can be used to calculate TEAD scores, as described in detail below.
[0006] Other signatures generated by discriminant function analysis (SPSS statistics, IBM, Armonk, NY) have been identified and are applicable to specific types of cancer (indications) and are used to classify TEAD-active tumors compared to TEAD-inactive tumors (as these are defined by TEAD-500) with an accuracy close to or very frequently reaching 100%. Specific, shorter signatures are associated with specific types of cancer. Shorter signatures include the best discriminant function and sometimes the minimum discriminant function. The discriminant function includes a gene set and a constant coefficient for the discriminant function. Each gene in the gene set is associated with a coefficient. For a given signature, the minimum discriminant function includes genes that are critical for 100% correct classification. Any missing data will introduce a certain degree of inaccuracy. For a given signature, the best discriminant function uses more predictive indicators, but when some data are missing, 100% correct classification of patients will still be achieved. According to one method, additional signatures (minimum and best discriminant functions) can be used to calculate the discriminant score (S), as described in detail later. According to another method, the best discriminant function may be used alternately to calculate the discriminant score (DS), as described in detail later.
[0007] The identified signatures can be used for a variety of clinical and research-related utilities, including, but not limited to, monitoring the activity of TEAD complexes and evaluating the pharmacodynamics of novel inhibitors of the TEAD pathway in vitro or in vivo, diagnosing tumors whose development or progression is attributed to TEAD complex activation, recruiting patients with TEAD activity to clinical trials designed to evaluate TEAD pathway inhibitors, predicting survival under, response to, and benefit from anti-TEAD pathway treatments, either alone or in combination with other treatments, estimating the proportion of cases in a cohort for each cancer indication or subtype in which TEAD-dependent transcription may be responsible for the development or progression of a tumor to become resistant to treatment, and measuring TEAD-dependent transcription in any tissue in the context of any condition, pathological or non-pathological, in the laboratory or clinic. abbreviation ACC adrenocortical carcinoma BID twice a day BLCA Bladder urothelial carcinoma BRCA invasive breast cancer CCLE Cancer Cell Line Encyclopedia CESC Cervical squamous cell carcinoma and cervical adenocarcinoma CHOL bile duct cancer CMS1 Consensus molecular classification of colorectal cancer 1 CMS2 Consensus molecular classification of colorectal cancer 2 CMS3 consensus molecular classification of colorectal cancer 3 CMS4 Consensus molecular classification of colorectal cancer 4 COAD Colon adenocarcinoma ddeR Relative TEAD activity score based on effector class (difference from control) deR Absolute TEAD activity score based on effector class dgR Absolute TEAD activity score based on the whole transcriptome level DLBC Lymphoid neoplasms Diffuse large B-cell lymphoma DMSO Dimethyl sulfoxide DN dominant negative ESCA Esophageal cancer GBM Glioblastoma multiforme GEO Gene Expression Omnibus GTEx Genotype-Tissue Expression Project HNSC Head and neck squamous cell carcinoma HuGO Human Genome Organization KICH renal chromophobe cell carcinoma KIRC Renal clear cell carcinoma KIRP Renal papillary cell carcinoma LGG Low-grade glioma LIHC Hepatocellular carcinoma LUAD Lung adenocarcinoma LUSC Lung squamous cell carcinoma MESO Mesothelioma NA Not applicable NCBI National Center for Biotechnology Information OV Ovarian serous cystadenocarcinoma PAAD Pancreatic adenocarcinoma PCPG Pheochromocytoma and paraganglioma PRAD Prostate adenocarcinoma QD once a day READ Rectal adenocarcinoma RT-qPCR Reverse transcription-quantitative polymerase chain reaction SARC sarcoma SCID severe combined immunodeficiency SKCM Cutaneous melanoma STAD Gastric adenocarcinoma TCGA The Cancer Genome Atlas TGCT Testicular germ cell tumor THCA Thyroid cancer THYM Thymoma UCEC Endometrial carcinoma UCS Uterine Carcinosarcoma BRIEF DESCRIPTION OF THE DRAWINGS
[0008] Figure 1 . Comparison of TEAD-500deR and dgR scores in experimental samples (N=1176).
[0009] Figure 2 Robustness of TEAD-500 scores. For our collection of 1112 experimental samples, two subsets of TEAD-500 (each with 10% of genes randomly removed) produced very similar TEAD activity scores.
[0010] Figure 3 AC. Dose-dependent regression of TEAD-500 score (A) and inhibition of CCN1 markers of TEAD activity at the RNA (B) and protein (C) levels by a benchmark chemical inhibitor of TEAD (K-975) in mesothelioma NCI-H226 cells grown in vitro.
[0011] Figure 4 AB. Validation of TEAD-500 labeling in vivo. MSTO-211H cells transfected with a doxycycline-inducible TEAD1-DN construct were implanted into SCID mice. When TEAD1-DN transcription was induced, xenografts began to regress (A), while a significant decrease in TEAD-500 scores was observed within 96 h (B).
[0012] Figure 5 AB. SCID mice implanted with malignant mesothelioma parental NCI-H226 cells were treated with 200 mg / kg BID of the benchmark TEAD inhibitor K-975 for 17 days (bottom gray line-square dots). The dose of 100 mg / kg BID was still active and almost tumor stagnant (dashed line), while the dose of 30 mg / kg BID was inactive (upper light gray line with black dots) (A). In this model, about 30%-40% inhibition of YAP1 / TEAD-dependent transcription within 24h (darker line) is sufficient to cause tumor regression (B).
[0013] Figure 6 .The distribution of TEAD-500 scores in tumors (TCGA primary tumors) was shifted toward higher values compared to normal tissues (GTEx or TCGA tumor-adjacent normal tissues). Primary tumors tended to have higher scores than adjacent normal tissues. Recurrent and metastatic tumors scored higher than primary tumors. Thus, YAP1 / TEAD-dependent transcription increases with tumorigenesis and tumor progression. Cell lines (CCLE) obtained much higher scores, and mesothelioma cell lines had the highest scores.
[0014] Figure 7 AB. Mean TEAD-500 score distribution in cervical cancer with YAP1 amplification (TCGA CESC cohort) compared to syngeneic tumors with diploid YAP1 (A) and in malignant mesothelioma tumors (TCGA MESO cohort) compared to all other TCGA primary tumors (B).
[0015] Figure 8 Overall survival of malignant mesothelioma patients (TCGA MESO cohort) with tumors having high or low scores for TEAD-dependent transcription as measured by TEAD-500.
[0016] Fig. 9 Overall survival of patients from all TCGA cancer types was combined compared to TEAD-dependent transcriptional levels scored by TEAD-500.
[0017] Fig.10 .Optimal discrimination of mesothelioma samples with active or inactive TEAD pathways.
[0018] Fig.11 Minimal discrimination of mesothelioma samples with active or inactive TEAD pathway.
[0019] Fig.12 .Comparison of the best and minimum discriminant scores. Summary of the invention
[0020] Provided herein are gene signatures (e.g., panels of biomarkers) that can be used for a variety of clinical and diagnostic applications, including, but not limited to, determining whether a subject responds to a particular treatment, monitoring the activity of a TEAD complex, evaluating the pharmacodynamics of inhibitors of the TEAD pathway in vitro or in vivo, diagnosing tumors whose development or evolution is attributed to TEAD complex activation, enrolling patients with active TEAD in clinical trials designed to evaluate TEAD pathway inhibitors, predicting survival, response to, and benefit from anti-TEAD pathway treatments, either alone or in combination with other treatments, estimating the proportion of cases in a cohort in which TEAD-dependent transcription may be responsible for tumor development or progression to become resistant to treatment, and measuring TEAD-dependent transcription in any tissue in the context of any condition, pathological or non-pathological, in the laboratory or clinic.
[0021] To obtain a gene signature, the activity of the TEAD complex in various types of individual tissue samples was evaluated by observing the relative expression of the top 500 most significantly differentially expressed genes affected by the reported experimental modulation of the TEAD complex. The TEAD-500 signature was derived from the top 500 most significantly differentially expressed genes by removing redundant or irrelevant genes.
[0022] We refer to this group here as "TEAD-500," which actually consists of approximately 482 genes. Up to 10% of the genes can be randomly removed from TEAD-500 without significantly compromising the accuracy of the results.
[0023] The present disclosure relates to a panel of nucleic acid biomarkers having N biomarkers, wherein N is an integer of at least 160 and less than or equal to about 482, and wherein the N biomarkers include nucleic acids capable of detecting the expression levels of any 80 to about 249 genes of gene set (1) (positive effector genes) and any 80 to about 233 genes of gene set (2) (negative effector genes).
[0024] The transcriptional signatures described herein can be obtained by measuring the expression levels of genes in a gene set, the gene set including any 220 to 249 genes (positive effect genes) of gene set (1) and any 210 to 233 genes (negative effect genes) of gene set (2) as listed below. Such transcriptional signatures or related gene sets are referred to herein as "TEAD signatures".
[0025] Embodiment 1. 249 positive effect genes (or gene set (1)) in TEAD-500: <h2 style=";text-align:left;direction:ltr">AASS, ABAT, ACAT2, ADAMTS1, ADM, ADRB2, AMOT, ANXA3, ARHGAP11A, ARHGDIB, AURKB, AVPI1, AXL, AZIN1, B4GALT4, BCAT1, BIRC5, BTG3, C4BPB, CAP2, CAV1 、CAVIN1、CCBE1、CCDC80、CCN1、CCN2、CDC25A、CDC6、CDCA3、CDCA4、CDCA5、C DCA8、CDH4、CDK2、CDK6、CDV3、CENPA、CENPI、CENPM、CENPN、CHRNB1、CHST13、 CKS2、CLDN1、CLIC3、CNN3、COBL、COL8A1、COTL1、CPA4、CRIM1、CRY1、CTH、CX CL1、CYTH3、DAPK1、DCLRE1B、DDAH1、DHCR7、DHFR、DIAPH3、DKK1、DLL1、DONSO N、DUSP14、DUT、EBP、EIF2AK3、EMG1、EPHA2、EPS8L2、ESM1、ETS1、EXO1、EXOS C2、F3、FAHD2A、FAM83D、FANCA、FAT4、FDPS、FEN1、FMR1、FST、FSTL1、FSTL3、G ADD45A、GADD45B、GINS1、GPC6、GPR176、GPRC5A、GPRC5B、GRAMD2B、HASPIN、 HEG1、HEXB、HPS5、HSPB11、IDI1、IGFBP7、IKBIP、IL6、ITGB2、JDP2、JPH2、KPN A2, KRT8, KRT80, LCA5, LHFPL6, LMCD1, LMNB2, LRP8, LRRFIP2, LSM5, LYPD6, LYRM1, MAD2L1, MAP6D1, MATN2, MATN3, MCM10, MCM2, MCM5, MDC1, METRNL, MIC B, MID1, MRPL33, MSRB3, MVD, MXRA7, NCAPD3, NEDD4, NEDD4L, NEK2, NEXN, NFIB, NNMT, NOC3L, NTN4, NUAK1, NUAK2, NUDCD1, NUP107, NUP37, OGFRL1, OLFML 3、OLR1、OXCT1、PAK2、PCBD1、PCNA、PDLIM2、PDZD2、PEPD、PHLPP1、PKMYT1、P KP2、PKP4、PLCE1、PLEKHA7、PLK2、PLOD2、PPIH、PRPS1、PRPS2、PRSS23、PSG2、PSG6, PSG7, PSG9, PVR, PXMP2, QDPR, QKI, RAB11FIP1, RAB32, RACGAP1, RBM24, RBMS2, RCN2, RFC4, RND3, RNF144B, ROR1, RPS24, SCD5, SCML1, SDC2, SEC 14L1, SGK1, SGMS2, SGTB, SH3RF1, SHCBP1, SKP2, SLC25A23, SLC25A3, SLC38A5, SLC3A2, SLC7A1, SLC7A5, SMPD4, SNAPC1, SNX24, SORT1, SPAG1, SPATA5, STK3, STX11, STXBP6, SUSD2, SUV39H1, SYDE2, TACC3, TAGLN, TEAD1, TEAD4, TENT5B, TGM2, THBS1, TK1, TMEM139, TMEM160, TNFAIP3, TNFRSF12A, TNNC1 , TPM1, TPX2, TRIP13, TSPAN2, TTF2, TUBB6, TUFT1, TYMS, UAP1, UBE2C, UGCG, UHRF1, VKORC1L1, WWC1, WWC2, YAP1, ZBED2, ZDHHC18, ZNF488, ZNF704, and,
[0026] Embodiment 2. 233 negative effector genes (or gene set (2)) in TEAD-500: <h2 style=";text-align:left;direction:ltr">AASDH、ABCA1、ABCC5、ABI3BP、ABLIM3、ACADVL、ACOT11、ACOX2、ACSL5、ADAM 28、AGL、AGPAT4、ALDH3A2、ANKRD12、ANKRD22、ANKRD29、ANKRD42、ANTXR2、A PBB3、ARAP3、ARHGEF2、ASF1A、ATP7A、ATXN1、BCL11B、BHLHE41、BMF、CA2、CA SP1、CBR3、CCNG2、CDC42EP4、CDK1、CEBPB、CELSR3、CLCN3、CLDN4、COL6A1、CO L6A2、CPE、CRABP2、CROT、CSRNP2、CSTA、CTNNBIP1、CTSB、CTSK、CXXC5、CYP1 B1、CYP27C1、DDR1、DEDD2、DHX32、DIAPH2、DSC2、DSG3、DUSP6、DYNC2LI1、ELN 、EPS8L3、ERAP2、FAM102A、FAM117B、FAM83B、FAM89B、FERMT1、FKBP2、FOS、F TH1、FXYD3、GDPD1、GOLGA5、GOLPH3L、GPNMB、GPRC5C、GRB10、GSN、HAS3、HBP1 、HDAC1、HDHD2、HEY1、HOXA5、IFI44、IGSF3、IGSF9、INTS3、IRAK2、IRF9、IRX 5、ITGA2、KCNMA1、KCNMB3、KCNN4、KIFAP3、KLF10、KLF13、KLHL3、KLK11、KRCC 1、KRIT1、KRTDAP、LMTK3、LRP10、LTBP4、LXN、LYPD3、MALL、MANSC1、MAPK13、 MARCKSL1、MFSD1、MFSD5、MGST2、MGST3、MLLT11、MLPH、MMP13、MSX2、MTMR11、 MTMR9、MTSS1、MYO1A、NAGK、NAPELD、NCOA3、NFIL3、NPAS2、NRIP1、OAS1、OA S2、OASL、OFD1、OSBPL7、OTUB2、OVOL1、PAG1、PAK1、PCDHB2、PCDHB9、PCGF3、P CMTD2、PERP、PHF21A、PIK3C2B、PIK3R1、PIK3R2、PIK3R3、PIP4P2、PJA2、PKI A、PLA2G4C、PNRC1、PPP1R11、PRRX2、PTPRE、PYGB、RAC2、RALGPS1、RAPGEFL1、RBM23, RBM45, RBM47, RBP1, REEP6, RGL2, RGS17, RHOC, S100A14, SAMD9, SEC14L2, SECISBP2, SH3PXD2A, SH3TC1, SHROOM2, SLC14A1, SLC1A2, SLC 30A9, SLC35C1, SLC37A2, SLC39A11, SLFN5, SLITRK6, SLK, SMOC1, SNCG, SP1, SPIRE2, SPRY4, SQSTM1, SRD5A3, SSPN, STMN3, STX1A, TBX3, TCF25, TDO2, TET2, TFF1, TLR3, TMC4, TMC7, TMEM140, TMEM144, TMEM45B, TP53INP1, TP63, TPD52L1, TRAPPC6B, TRIB1, TRIB2, TRIM13, TRIM31, TRIM38, TRIOBP, TRIP11, TSC22D1, TSPAN1, TTC17, TTLL3, TUBB3, UBC, ULK1, VAMP8, VGF, VPS52, VSNL1, WDR13, ZCWPW1, ZNF292, ZNF467, ZNF75D, ZSWIM7. ,
[0027] Note that some HuGO-approved gene symbols, including the classic YAP1 activity markers CCN1 (formerly CYR61) and CCN2 (formerly CTGF), have not yet been implemented in The Cancer Genome Atlas (TCGA), but have been adopted in other datasets.
[0028] In some embodiments, a panel comprising nucleic acids capable of detecting N genes is contemplated, wherein N is an integer of at least 160 and less than or equal to about 482, and wherein the N genes include 80 to 249 of any of the following genes (positive effector genes) of the following gene set (1): AASS, ABAT, ACAT2, ADAMTS1, ADM, ADRB2, AMOT, ANXA3, ARHGAP11A, ARHGDIB, AURKB, AVPI1, AXL, AZIN1, B4GALT4, BCAT1, BIRC5, BTG3, C4BPB, CAP2, CAV1, CAVIN1, CCBE1, CCDC80, CCN1, CCN2, CDC25A, CDC6, CDCA3, CDCA4, CDCA5, CDCA8, CDH4, CDK2, CDK6, CDV3, CENPA, CENPI, CENPM, CENPN, CHRNB1, CHST13, CKS2, CLDN1, CLIC3, CNN3, COBL, COL 8A1, COTL1, CPA4, CRIM1, CRY1, CTH, CXCL1, CYTH3, DAPK1, DCLRE1B, DDAH1, DHCR7, DHFR, DIAPH3, DKK1, DLL1, DONSON, DUSP14, DUT, EBP, EIF2AK3, EMG1, EPHA2, EPS8L2, ESM1, ETS1, EXO1, EXOSC2, F3, FAHD2A, FAM83D, FANCA, FAT4, FDPS, FEN1, FMR1, FST, FSTL1, FSTL3, GADD45A, GADD45B, GINS1, GPC6, GPR 176. GPRC5A, GPRC5B, GRAMD2B, HASPIN, HEG1, HEXB, HPS5, HSPB11, IDI1, IGFBP7, IKBIP, IL6, ITGB2, JDP2, JPH2, KPNA2, KRT8, KRT80, LCA5, LHFPL6, LMC D1, LMNB2, LRP8, LRRFIP2, LSM5, LYPD6, LYRM1, MAD2L1, MAP6D1, MATN2, MATN3, MCM10, MCM2, MCM5, MDC1, METRNL, MICB, MID1, MRPL33, MSRB3, MVD, MXRA7 , NCAPD3, NEDD4, NEDD4L, NEK2, NEXN, NFIB, NNMT, NOC3L, NTN4, NUAK1, NUAK2, NUDCD1, NUP107, NUP37, OGFRL1, OLFML3, OLR1, OXCT1, PAK2, PCBD1, PCNA,PDLIM2, PDZD2, PEPD, PHLPP1, PKMYT1, PKP2, PKP4, PLCE1, PLEKHA7, PLK2, PLOD2, PPIH, PRPS1, PRPS2, PRSS23, PSG2, PSG6, PSG7, PSG9, PVR, PXMP2, QDPR, QKI, RAB11FIP1, RAB32, RACGAP1, RBM24, RBMS2, RCN2, RFC4, RND3, RNF144B, ROR1, RPS24, SCD5, SCML1, SDC2, SEC14L1, SGK1, SGMS2, SGTB, SH3RF1, SHCBP1, SKP2, SLC25A23, SLC25A3, SLC38A5, SLC3A2, SLC7A1, SLC7A5, SMPD4, SNAPC1, SNX24, SORT1, SPAG1, SPATA5, STK3, STX11, STXBP6, SUSD2, SUV39H1, SYDE2, TACC3, TAGLN, TEAD1, TEAD4, TENT5B, TGM2, THBS1, TK1, TMEM139, TMEM160, TNFAIP3, TNFRSF12A, TNNC1, TPM1, TPX2, TRIP13, TSPAN2, TTF2, TUBB6, TUFT1, TYMS, UAP1, UBE2C, UGCG, UHRF1, VKORC1L1, WWC1, WWC2, YAP1, ZBED2, ZDHHC18, ZNF488, and ZNF704; and,
[0029] The N genes include any of the following 80 to 233 genes (negative effect genes) in gene set (2): AASDH, ABCA1, ABCC5, ABI3BP, ABLIM3, ACADVL, ACOT11, ACOX2, ACSL5, ADAM28, AGL, AGPAT4, ALDH3A2, ANKRD12, ANKRD22, ANKRD29, ANKRD42, ANTXR2, APBB3, ARAP3, ARHGEF2, ASF1A, ATP7A, ATXN1, BCL11B, BHLHE41, BMF, CA2, CASP1, CBR3, CCNG2, CDC42EP4, CDK 1. CEBPB, CELSR3, CLCN3, CLDN4, COL6A1, COL6A2, CPE, CRABP2, CROT, CSRNP2, CSTA, CTNNBIP1, CTSB, CTSK, CXXC5, CYP1B1, CYP27C1, DDR1, DEDD2, DHX3 2. DIAPH2, DSC2, DSG3, DUSP6, DYNC2LI1, ELN, EPS8L3, ERAP2, FAM102A, FAM117B, FAM83B, FAM89B, FERMT1, FKBP2, FOS, FTH1, FXYD3, GDPD1, GOLGA5, GOL PH3L, GPNMB, GPRC5C, GRB10, GSN, HAS3, HBP1, HDAC1, HDHD2, HEY1, HOXA5, IFI44, IGSF3, IGSF9, INTS3, IRAK2, IRF9, IRX5, ITGA2, KCNMA1, KCNMB3, KCN N4, KIFAP3, KLF10, KLF13, KLHL3, KLK11, KRCC1, KRIT1, KRTDAP, LMTK3, LRP10, LTBP4, LXN, LYPD3, MALL, MANSC1, MAPK13, MARCKSL1, MFSD1, MFSD5, MGST 2. MGST3, MLLT11, MLPH, MMP13, MSX2, MTMR11, MTMR9, MTSS1, MYO1A, NAGK, NAPEPLD, NCOA3, NFIL3, NPAS2, NRIP1, OAS1, OAS2, OASL, OFD1, OSBPL7, OTUB 2. OVOL1, PAG1, PAK1, PCDHB2, PCDHB9, PCGF3, PCMTD2, PERP, PHF21A, PIK3C2B, PIK3R1, PIK3R2, PIK3R3, PIP4P2, PJA2, PKIA, PLA2G4C, PNRC1, PPP1R11,<h2 style=";text-align:left;direction:ltr">PRRX2、PTPRE、PYGB、RAC2、RALGPS1、RAPGEFL1、RBM23、RBM45、RBM47、RBP1、RE EP6、RGL2、RGS17、RHOC、S100A14、SAMD9、SEC14L2、SECISBP2、SH3PXD2A、SH3T C1, SHROOM2, SLC14A1, SLC1A2, SLC30A9, SLC35C1, SLC37A2, SLC39A11, SLFN5, SLITRK6, SLK, SMOC1, SNCG, SP1, SPIRE2, SPRY4, SQSTM1, SRD5A3, SSPN, STMN 3、STX1A、TBX3、TCF25、TDO2、TET2、TFF1、TLR3、TMC4、TMC7、TMEM140、TMEM144 、TMEM45B、TP53INP1、TP63、TPD52L1、TRAPPC6B、TRIB1、TRIB2、TRIM13、TRIM3 1、TRIM38、TRIOBP、TRIP11、TSC22D1、TSPAN1、TTC17、TTLL3、TUBB3、UBC、ULK1 、VAMP8、VGF、VPS52、VSNL1、WDR13、ZCWPW1、ZNF292、ZNF467、ZNF75D、ZSWIM7。、<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0030] In some embodiments, N is an integer of 482, and wherein the 482 genes include the following 249 positive effector genes: AASS, ABAT, ACAT2, ADAMTS1, ADM, ADRB2, AMOT, ANXA3, ARHGAP11A, ARHGDIB, AURKB, AVPI1, AXL, AZIN1, B4GALT4, BCAT1, BIRC5, BTG3, C4BPB, CAP2, CAV1, CAVIN1, CCBE1, CCDC80, CCN1, CCN2, CDC25A, CDC6, CDCA3, CDCA4, CDCA5, CDCA8, CDH4, CDK2, CDK 6. CDV3, CENPA, CENPI, CENPM, CENPN, CHRNB1, CHST13, CKS2, CLDN1, CLIC3, CNN3, COBL, COL8A1, COTL1, CPA4, CRIM1, CRY1, CTH, CXCL1, CYTH3, DAPK1, D CLRE1B, DDAH1, DHCR7, DHFR, DIAPH3, DKK1, DLL1, DONSON, DUSP14, DUT, EBP, EIF2AK3, EMG1, EPHA2, EPS8L2, ESM1, ETS1, EXO1, EXOSC2, F3, FAHD2A, FAM8 3D, FANCA, FAT4, FDPS, FEN1, FMR1, FST, FSTL1, FSTL3, GADD45A, GADD45B, GINS1, GPC6, GPR176, GPRC5A, GPRC5B, GRAMD2B, HASPIN, HEG1, HEXB, HPS5, H SPB11, IDI1, IGFBP7, IKBIP, IL6, ITGB2, JDP2, JPH2, KPNA2, KRT8, KRT80, LCA5, LHFPL6, LMCD1, LMNB2, LRP8, LRRFIP2, LSM5, LYPD6, LYRM1, MAD2L1, MAP 6D1, MATN2, MATN3, MCM10, MCM2, MCM5, MDC1, METRNL, MICB, MID1, MRPL33, MSRB3, MVD, MXRA7, NCAPD3, NEDD4, NEDD4L, NEK2, NEXN, NFIB, NNMT, NOC3L, N TN4, NUAK1, NUAK2, NUDCD1, NUP107, NUP37, OGFRL1, OLFML3, OLR1, OXCT1, PAK2, PCBD1, PCNA, PDLIM2, PDZD2, PEPD, PHLPP1, PKMYT1, PKP2, PKP4, PLCE1,<h2 style=";text-align:left;direction:ltr">PLEKHA7、PLK2、PLOD2、PPIH、PRPS1、PRPS2、PRSS23、PSG2、PSG6、PSG7、PSG9、PVR、 PXMP2、QDPR、QKI、RAB11FIP1、RAB32、RACGAP1、RBM24、RBMS2、RCN2、RFC4、RND3、RN F144B, ROR1, RPS24, SCD5, SCML1, SDC2, SEC14L1, SGK1, SGMS2, SGTB, SH3RF1, SHCBP1, SKP2, SLC25A23, SLC25A3, SLC38A5, SLC3A2, SLC7A1, SLC7A5, SMPD4, SNAPC1 SNX24、SORT1、SPAG1、SPATA5、STK3、STX11、STXBP6、SUSD2、SUV39H1、SYDE2、TACC 3、TAGLN、TEAD1、TEAD4、TENT5B、TGM2、THBS1、TK1、TMEM139、TMEM160、TNFAIP3、TN FRSF12A、TNNC1、TPM1、TPX2、TRIP13、TSPAN2、TTF2、TUBB6、TUFT1、TYMS、UAP1、UB E2C、UGCG、UHRF1、VKORC1L1、WWC1、WWC2、YAP1、ZBED2、ZDHHC18、ZNF488、ZNF704。、<h2 style=";text-align:left;direction:ltr"> <h2 style=";text-align:left;direction:ltr">
[0031] In some embodiments, N is an integer of 482, and wherein the 482 genes include the following 233 negative effector genes: AASDH, ABCA1, ABCC5, ABI3BP, ABLIM3, ACADVL, ACOT11, ACOX2, ACSL5, ADAM28, AGL, AGPAT4, ALDH3A2, ANKRD12, ANKRD22, ANKRD29, ANKRD42, ANTXR2, APBB3, ARAP3, ARHGEF2, ASF1A, ATP7A, ATXN1, BCL11B, BHLHE41, BMF, CA2, CASP1, CBR3, CCNG2, CDC4 2EP4, CDK1, CEBPB, CELSR3, CLCN3, CLDN4, COL6A1, COL6A2, CPE, CRABP2, CROT, CSRNP2, CSTA, CTNNBIP1, CTSB, CTSK, CXXC5, CYP1B1, CYP27C1, DDR1, DE DD2, DHX32, DIAPH2, DSC2, DSG3, DUSP6, DYNC2LI1, ELN, EPS8L3, ERAP2, FAM102A, FAM117B, FAM83B, FAM89B, FERMT1, FKBP2, FOS, FTH1, FXYD3, GDPD1, GO LGA5, GOLPH3L, GPNMB, GPRC5C, GRB10, GSN, HAS3, HBP1, HDAC1, HDHD2, HEY1, HOXA5, IFI44, IGSF3, IGSF9, INTS3, IRAK2, IRF9, IRX5, ITGA2, KCNMA1, KC NMB3, KCNN4, KIFAP3, KLF10, KLF13, KLHL3, KLK11, KRCC1, KRIT1, KRTDAP, LMTK3, LRP10, LTBP4, LXN, LYPD3, MALL, MANSC1, MAPK13, MARCKSL1, MFSD1, MF SD5, MGST2, MGST3, MLLT11, MLPH, MMP13, MSX2, MTMR11, MTMR9, MTSS1, MYO1A, NAGK, NAPEPLD, NCOA3, NFIL3, NPAS2, NRIP1, OAS1, OAS2, OASL, OFD1, OSB PL7, OTUB2, OVOL1, PAG1, PAK1, PCDHB2, PCDHB9, PCGF3, PCMTD2, PERP, PHF21A, PIK3C2B, PIK3R1, PIK3R2, PIK3R3, PIP4P2, PJA2, PKIA, PLA2G4C, PNRC1,PPP1R11, PRRX2, PTPRE, PYGB, RAC2, RALGPS1, RAPGEFL1, RBM23, RBM45, RBM47, RBP1, REEP6, RGL2, RGS17, RHOC, S100A14, SAMD9, SEC14L2, SECISBP2, SH3PXD2 A. SH3TC1, SHROOM2, SLC14A1, SLC1A2, SLC30A9, SLC35C1, SLC37A2, SLC39A11, SLFN5, SLITRK6, SLK, SMOC1, SNCG, SP1, SPIRE2, SPRY4, SQSTM1, SRD5A3, SSPN, STMN3, STX1A, TBX3, TCF25, TDO2, TET2, TFF1, TLR3, TMC4, TMC7, TMEM140, TMEM144, TMEM45B, TP53INP1, TP63, TPD52L1, TRAPPC6B, TRIB1, TRIB2, TRIM13, TRI M31, TRIM38, TRIOBP, TRIP11, TSC22D1, TSPAN1, TTC17, TTLL3, TUBB3, UBC, ULK1, VAMP8, VGF, VPS52, VSNL1, WDR13, ZCWPW1, ZNF292, ZNF467, ZNF75D and ZSWIM7. ,
[0032] In some embodiments, the panels of the present disclosure can be used to measure TEAD-dependent transcription levels of genes in a sample from a subject having or suspected of having cancer, the measurement comprising: isolating a biological sample from the subject and detecting the expression level of each gene of the panel.
[0033] In some embodiments, the panels of the present disclosure can be used to characterize a subject as having a TEAD-active or TEAD-inactive cancer, the characterization comprising: isolating a biological sample from a subject having or suspected of having cancer, and detecting the expression level of each gene of the panel, wherein if dgR or deR is greater than about 0.055, the subject has a TEAD-active cancer.
[0034] In some embodiments, the panel of the disclosure of the present disclosure can be used to predict whether a subject will have a positive response to a TEAD pathway inhibitor, the prediction comprising: isolating a biological sample from a subject having or suspected of having cancer, and detecting the expression level of each gene of the panel, wherein if dgR or deR is greater than about 0.055, the subject is likely to have a positive response to a TEAD pathway inhibitor.
[0035] In some embodiments, the present disclosure relates to a transcriptional signature ("TEAD signature") obtained by measuring the expression levels of genes of a gene set, wherein the gene set includes any 220 to 249 genes of gene set (1) (positive effector genes) and any 210 to 233 genes of gene set (2) (negative effector genes).
[0036] Transcriptional signatures ("TEAD signatures") can be used to measure TEAD activity in cancer. Transcriptional signatures can be used for a variety of applications, including predicting the likelihood that a subject will respond to treatment with a TEAD pathway inhibitor, selecting patients for clinical trials, evaluating the efficacy of TEAD pathway inhibitor molecules, and predicting survival under anti-TEAD pathway therapy, response to the therapy, and benefit from the therapy.
[0037] In some embodiments, the present disclosure relates to the use of a transcriptional signature for measuring TEAD activity of a cancer in a subject in need thereof, wherein the transcriptional signature is obtained by measuring the expression levels of genes of a gene set in a biological sample of a tumor of the cancer, wherein the gene set includes any 220 to 249 genes of gene set (1) (positive effector genes) and any 210 to 233 genes of gene set (2) (negative effector genes).
[0038] In some embodiments, the present disclosure relates to the use of a transcriptional signature for characterizing TEAD activity of a cancer in a subject in need thereof, wherein the transcriptional signature is obtained by measuring the expression levels of genes of a gene set in a biological sample of a tumor of the cancer, wherein the gene set includes any 220 to 249 genes of gene set (1) (positive effector genes) and any 210 to 233 genes of gene set (2) (negative effector genes).
[0039] A transcriptional signature according to the present disclosure ("TEAD signature") can be used to determine a TEAD score.
[0040] In some embodiments, the TEAD score is calculated according to any of the following methods: Method 1: Calculate the dgR score as follows: 1. For each gene tested (e.g., the whole transcriptome), the expression level of the gene is converted to a fractional rank, which, according to the definition herein, is the rank of the gene (i.e., where the expression level falls within a list of all genes tested, where the gene with the lowest expression level is assigned a rank of 1, the gene with the second highest expression level is assigned a rank of 2, and so on, until the highest expressed gene is assigned the highest rank; equal expression levels are assigned an average rank, e.g., two genes with zero expression are assigned a rank of 1.5) divided by the number of genes tested. 2. Isolate the genes in gene set (1) (positive effect genes) and calculate their mean score rank (MFR-positive) 3. Isolate the genes in gene set (2) (negative effect genes) and calculate their mean score rank (MFR-negative) 4. Calculate the dgR score as MFR-positive-MFR-negative Method 2: Calculate the deR score as follows: 1. Separation of genes (positive effector genes and negative effector genes) from gene sets (1) and (2) in the TEAD-500 panel. 2. For each gene tested, the expression level of the gene is converted to a fractional rank, which, according to the definition herein, is the rank of the gene (i.e., where the expression level falls within the list of all genes tested, where the gene with the lowest expression level is assigned a rank of 1, the gene with the second highest expression level is assigned a rank of 2, and so on, until the highest expressed gene is assigned the highest rank; equal expression levels are assigned an average rank, e.g., two genes with zero expression are assigned a rank of 1.5) divided by the number of genes tested. 3. Isolate positive effectors and calculate their mean fractional rating (MFR-positive) 4. Isolate negative effectors and calculate their mean fractional rating (MFR-negative) 5. Calculate the deR score as MFR-positive-MFR-negative
[0041] The dgR and deR scores can be used to determine whether a subject has a TEAD-active cancer or a TEAD-inactive cancer. If the dgR or deR score is greater than about 0.055, the cancer is TEAD-active. If the dgR or deR score is less than or equal to about 0.055, the cancer is TEAD-inactive.
[0042] In some embodiments, the gene set of the transcriptional signature ("TEAD signature") can include 430 to 482 genes.
[0043] In some embodiments, the gene set of the transcriptional signature ("TEAD signature") can include 430, 431, 432, 433, 434, 436, 437, or 482 genes.
[0044] In some embodiments, the cancer may be a cancer including a solid tumor.
[0045] In some embodiments, the solid tumor can be in the lung, colon, ovary, cervix, uterus, peritoneum, testicle, penis, tongue, lymph node, pancreas, bone, breast, prostate, soft tissue, connective tissue, kidney, liver, brain, thyroid, or skin.
[0046] In some embodiments, the cancer, including solid tumors, can be selected from: adrenocortical carcinoma, bladder urothelial carcinoma, invasive breast cancer, cervical squamous cell carcinoma and cervical adenocarcinoma, bile duct carcinoma, consensus molecular classification 1 of colorectal cancer, consensus molecular classification 2 of colorectal cancer, consensus molecular classification 3 of colorectal cancer, consensus molecular classification 4 of colorectal cancer, colon adenocarcinoma, lymphoid tumor diffuse large B-cell lymphoma, esophageal cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, brain low-grade glioma, hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, mesothelioma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma and paraganglioma, prostate adenocarcinoma, rectal adenocarcinoma, sarcoma, skin melanoma, gastric adenocarcinoma, testicular germ cell tumor, thyroid cancer, thymoma, endometrial carcinoma and uterine carcinosarcoma.
[0047] In some embodiments, the use of transcriptional tags ("TEAD tags") may include:
[0048] a) measuring the expression level of a gene in a transcriptome obtained from said biological sample,
[0049] b) for each gene of the gene set, converting the expression level of the gene obtained in step a) into a fractional rank by dividing the rank of the gene by the number of genes from the transcriptome,
[0050] c) separating the score ranks obtained for the genes of gene set (1) from the score ranks obtained in step b) and calculating their average score rank (MFR-positive),
[0051] d) separating the score ranks obtained for the genes of gene set (2) from the score ranks obtained in step b) and calculating their average score rank (MFR-negative), and
[0052] e) Calculate the dgR score as MFR-positive-MFR-negative;
[0053] or
[0054] a) measuring the expression level of each gene of the gene set in the biological sample,
[0055] b) for each gene of the gene set, converting the expression level of the gene obtained in step a) into a fractional rank by dividing the rank of the gene by the number of genes from the gene set,
[0056] c) separating the score ranks obtained for the genes of gene set (1) from the score ranks obtained in step b) and calculating their average score rank (MFR-positive),
[0057] d) separating the score ranks obtained for the genes of gene set (2) from the score ranks obtained in step b) and calculating their average score rank (MFR-negative), and
[0058] e) calculating the deR score as MFR-positive-MFR-negative;
[0059] wherein when the dgR or the deR score is greater than about 0.055, then the cancer is TEAD-active, and when the dgR or deR score is less than or equal to about 0.055, then the cancer is TEAD-inactive;
[0060] In some embodiments, the transcriptional tags can be reduced to shorter tags. Those shorter tags are referred to below as "short TEAD tags".
[0061] The "short TEAD signature" is obtained by measuring the gene expression levels of a reduced number of genes and is specific for a given cancer.
[0062] In some embodiments, the present disclosure relates to the use of a transcriptional signature for measuring TEAD activity of a cancer in a subject in need thereof, wherein the transcriptional signature is obtained by measuring the expression levels of genes of a gene set in a biological sample of a tumor of the cancer, wherein the gene set is selected from set a) to mmmm) of Table 1 below ("short TEAD signature").
[0063] In some embodiments, the disclosure relates to the use of a transcriptional signature for characterizing TEAD activity of a cancer in a subject in need thereof, wherein the transcriptional signature is obtained by measuring the expression levels of genes of a gene set in a biological sample of a tumor of the cancer, wherein the gene set is selected from Set a) to mmmm) of Table 1 below (“Short TEAD Signature”).
[0064] In some embodiments, the present disclosure relates to a panel of nucleic acid biomarkers comprising nucleic acids capable of detecting the expression level of each gene within any one of the following gene sets a) to mmmm): Table 1. Gene sets for specific cancer indications (“short TEAD signature”)
[0065] In some embodiments, the gene set for the "short TEAD signature" can be associated with a cancer selected from the following: adrenocortical carcinoma (ACC) tumors; bladder urothelial carcinoma (BLCA) tumors; invasive breast cancer (BRCA); BRCA basal tumors; BRCA non-basal tumors; cervical squamous cell carcinoma or cervical adenocarcinoma (CESC) tumors; bile duct carcinoma (CHOL) tumors; colon adenocarcinoma (COAD) tumors; COAD CMS1 tumors; COAD CMS2 tumors; COAD CMS4 tumors; lymphoid tumors diffuse large B-cell lymphoma (DLBC) tumors; esophageal carcinoma (ESCA) tumors; glioblastoma multiforme (GBM) tumors; head or neck squamous cell carcinoma (HNSC) tumors; kidney chromophobe cell carcinoma (KICH) tumors; kidney clear cell carcinoma (KIRC) tumors; kidney papillary cell carcinoma (KIRP) tumors; brain low grade glioma (LGG) tumors; hepatocellular carcinoma (LIHC) tumors; LIHC S1 tumors; LIHC S2 tumors; LIHC S3 tumors; lung adenocarcinoma (LUAD) tumors; LUAD proximal inflammatory tumors; LUAD proximal proliferative tumors; lung squamous cell carcinoma (LUSC) tumors; LUSC basic tumors; LUSC classic tumors; LUSC primary tumors; LUSC secretory tumors; malignant mesothelioma (MESO) tumors; ovarian serous cystadenocarcinoma (OV) tumors; OV differentiated tumors; OV immunoreactive tumors; OV mesenchymal tumors; OV proliferative tumors; pancreatic adenocarcinoma (PAAD) tumors; rectal adenocarcinoma (READ) tumors; READ CMS1 tumors; READ CMS2 tumors; READ CMS4 tumors; READ unclassifiable tumors; sarcoma (SARC) tumors; cutaneous melanoma (SKCM) tumors; SKCM immune tumors; SKCM keratin tumors; SKCM MITF low-expressing tumors; gastric adenocarcinoma (STAD) tumors; STAD MSI tumors; STAD MSS_EMT tumors; STAD MSS_TP53 tumors; STAD MSS_TP53+ tumors; testicular germ cell tumor (TGCT) tumors; thyroid carcinoma (THYM) tumors; endometrial carcinoma (UCEC) tumors; and uterine carcinosarcoma (UCS) tumors.
[0066] The "short TEAD tag" can be used in the method for calculating the discrimination score (S) (method 3) or (DS) (method 4).
[0067] Method 3: Determine the discrimination score (S).
[0068] To reduce the dimensionality of the test, a subset of the most informative genes applicable to a particular cancer type in the TEAD-500 set was determined. These are the groups with fewer genes that predict the status (active or inactive) of the TEAD complex in samples from a given cancer indication or subtype.
[0069] To determine the TEAD-active or TEAD-inactive status of a sample, the fractional rank of the genes in the optimal or minimal set is multiplied by the corresponding coefficient in parentheses. The products are summed to give a discriminant score (S). The discriminant score (S) is compared to the centroids of the TEAD-active (A) and TEAD-inactive (I) groups, which are provided for each corresponding cancer indication or subtype. If (S) is closer to (A) than to (I), the sample is classified as TEAD-active. Otherwise, the sample is classified as TEAD-inactive.
[0070] For example, the expression levels are measured, the fractional ranks of the test genes are calculated and multiplied by the corresponding coefficients in parentheses. The products are summed to give a discriminant score (S). Then one essentially applies the following calculation: max(S,A) - min(S,A) < max(S,I) - min(S,I), as follows: Compare (S) to the centroid of TEAD-active (A) and select the maximum value. Thus, if (S) is 5 and (A) is -268.9, one would select 5. Compare (S) and (A) and select the minimum value. Thus, if (S) is 5 and (A) is -268.9, one would select -268.9. Then compare (S) and (I) and select the maximum value. Thus, if (S) is 5 and (I) is 22.1, one would select 22.1. Then compare (S) and (I) and select the minimum value. Thus, if (S) is 5 and (I) is 22.1, one would select 5. Then ask if 5 minus negative 268.9 is less than 22.1 minus 5 (i.e., is 5 - (-268.9) < 22.1 - 5). If so, the cancer is TEAD-active. If not, the cancer is TEAD-inactive. In this hypothetical example, the cancer is TEAD-inactive because 273.9 is not less than 17.1.
[0071] As an alternative method for scoring the discriminant function, one can consider the mean between the centroids provided for TEAD-active (A) and TEAD-inactive (I), e.g., the mean between (0.5 and -5.7) = -2.6. If the calculated score > -2.6, the sample can be considered TEAD-inactive. If not, it may be considered TEAD-active.
[0072] The following embodiments, embodiments 3-59, provide alternative groups that can be used for the methods and uses described herein, wherein the methods / uses are directed to specific cancer types. For most embodiments, there are two useful groups - "optimal discriminant function" and "minimum discriminant function". The term "optimal" should not be interpreted as better than the minimum discriminant function. Table 2. Best and least discriminant predictive indices for gene sets for specific cancer indications
[0073] In some embodiments, the panel can be used to characterize a subject as having a TEAD-active cancer or a TEAD-inactive cancer or to predict whether a subject will respond positively to a TEAD pathway inhibitor, and the use may include:
[0074] - Determine the expression level of each test gene;
[0075] -determine the score rank for each gene;
[0076] -Multiply the score rank of each gene by the corresponding coefficient shown in parentheses below;
[0077] - Sum the products to give a discrimination score (S);
[0078] - Compare the discrimination score (S) with the centroids of the TEAD-active (A) and TEAD-inactive (I) groups;
[0079] - Determine whether (S) is closer to (A) than to (I) according to the formula max(S,A) - min(S,A) < max(S,I) - min(S,I); and
[0080] - If (S) is closer to (A) than to (I), then characterize the sample as TEAD-active, where the above embodiments (or sets) show the coefficients and centroids of each set from a) to mmmm).
[0081] In some embodiments, the use of the "short TEAD tag" according to the present disclosure may enable when the cancer is
[0082] - For adrenocortical carcinoma (ACC) tumors, the gene set of the transcriptional tag is gene set a) or b);
[0083] - For bladder urothelial carcinoma (BLCA) tumors, the gene set of the transcriptional tag is gene set c);
[0084] - For invasive breast carcinoma (BRCA) tumors, the gene set of the transcriptional tag is gene set d);
[0085] - For BRCA basal tumors, the gene set of the transcriptional tag is gene set e) or f);
[0086] - For BRCA non-basal tumors, the gene set of the transcriptional tag is gene set g) or h);
[0087] - For cervical squamous cell carcinoma or cervical adenocarcinoma (CESC) tumors, the gene set of the transcriptional tag is gene set i);
[0088] - For cholangiocarcinoma (CHOL) tumors, the gene set of the transcriptional tag is gene set j) or k);
[0089] - For colon adenocarcinoma (COAD) tumors, the gene set of the transcriptional tag is gene set l);
[0090] - For COAD CMS1 tumors, the gene set of the transcriptional tag is gene set m) or n);
[0091] - For COAD CMS2 tumors, the gene set of the transcriptional tag is gene set o) or p);
[0092] -COAD CMS4 tumor, the gene set of the transcriptional signature is gene set q) or q1);
[0093] - lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) tumor, the gene set of the transcriptional signature is gene set r) or s);
[0094] -esophageal cancer (ESCA) tumor, the gene set of the transcriptional signature is gene set t) or u);
[0095] - When the tumor is a glioblastoma multiforme (GBM), the gene set of the transcriptional signature is gene set v) or w);
[0096] -head or neck squamous cell carcinoma (HNSC) tumor, then the gene set of the transcriptional signature is gene set x);
[0097] -renal chromophobe cell carcinoma (KICH) tumor, the gene set of the transcriptional signature is gene set y) or z);
[0098] -renal clear cell carcinoma (KIRC) tumor, the gene set of the transcriptional signature is gene set aa);
[0099] -kidney papillary cell carcinoma (KIRP) tumor, the gene set of the transcriptional signature is gene set bb) or cc);
[0100] - When the tumor is a low-grade glioma (LGG) tumor, the gene set of the transcriptional signature is gene set dd) or ee);
[0101] -hepatocellular carcinoma (LIHC) tumor, then the gene set of the transcriptional signature is the gene set ff);
[0102] -LIHC S1 tumor, the gene set of the transcriptional signature is gene set gg) or hh);
[0103] -LIHC S2 tumor, the gene set of the transcriptional signature is gene set ii) or jj);
[0104] -LIHC S3 tumor, the gene set of the transcriptional signature is gene set kk) or ll);
[0105] - lung adenocarcinoma (LUAD) tumor, the gene set of the transcriptional signature is the gene set mm);
[0106] -LUAD proximal inflammatory tumor, the gene set of the transcriptional signature is gene set nn) or oo);
[0107] -LUAD proximal proliferative tumor, the gene set of the transcriptional signature is gene set pp) or qq);
[0108] - lung squamous cell carcinoma (LUSC) tumor, the gene set of the transcriptional signature is gene set rr);
[0109] -LUSC basal tumor, the gene set of the transcriptional signature is gene set ss) or tt);
[0110] -LUSC classic tumor, the gene set of the transcriptional signature is gene set uu);
[0111] -LUSC primary tumor, the gene set of the transcriptional signature is gene set vv) or ww);
[0112] -LUSC secretory tumor, the gene set of the transcriptional signature is gene set xx) or yy);
[0113] -Malignant mesothelioma (MESO) tumor, the gene set of the transcriptional signature is gene set zz) or aaa);
[0114] -Ovarian serous cystadenocarcinoma (OV) tumor, the gene set of the transcriptional signature is gene set bbb);
[0115] -OV differentiated tumor, the gene set of the transcriptional signature is the gene set ccc) or ddd);
[0116] -OV immunoreactive tumor, the gene set of the transcriptional signature is gene set eee) or fff);
[0117] -OV mesenchymal tumor, the gene set of the transcriptional signature is the gene set ggg) or hhh);
[0118] -OV proliferative tumor, the gene set of the transcriptional signature is gene set iii) or jjj);
[0119] - pancreatic adenocarcinoma (PAAD) tumor, the gene set of the transcriptional signature is gene set kkk) or kkk1);
[0120] -rectal adenocarcinoma (READ) tumor, the gene set of the transcriptional signature is gene set lll);
[0121] -READ CMS1 tumor, then the gene set of the transcriptional signature is the gene set mmm);
[0122] -READ CMS2 tumor, the gene set of the transcriptional signature is gene set nnn) or ooo);
[0123] -READ CMS4 tumor, the gene set of the transcriptional signature is the gene set ppp) or ppp1);
[0124] -READ unclassifiable tumor, the gene set of the transcriptional signature is gene set qqq) or qqq1);
[0125] -sarcoma (SARC) tumor, the gene set of the transcriptional signature is gene set rrr);
[0126] -skin melanoma (SKCM) tumor, the gene set of the transcriptional signature is gene set sss);
[0127] -SKCM immunotherapy, then the gene set of the transcriptional signature is gene set ttt);
[0128] -SKCM keratin tumor, the gene set of the transcriptional signature is gene set uuu) or vvv);
[0129] -When the tumor has low expression of SKCM MITF, the gene set of the transcriptional signature is the gene set www) or xxx);
[0130] - gastric adenocarcinoma (STAD) tumor, then the gene set of the transcriptional signature is gene set yyy);
[0131] -STAD MSI tumor, the gene set of the transcriptional signature is gene set zzz) or aaaa);
[0132] -STAD MSS_EMT tumor, the gene set of the transcriptional signature is gene set bbbb) or cccc);
[0133] -STAD MSS_TP53-tumor, the gene set of the transcriptional signature is gene set dddd) or eeee);
[0134] -STAD MSS_TP53+ tumor, the gene set of the transcriptional signature is the gene set ffff) or gggg);
[0135] -testicular germ cell tumor (TGCT) tumor, the gene set of the transcriptional signature is gene set hhhh) or iiii);
[0136] -thyroid cancer (THYM) tumor, the gene set of the transcriptional signature is gene set jjjj);
[0137] -endometrial carcinoma (UCEC) tumor, the gene set of the transcriptional signature is gene set kkkk); and
[0138] -uterine carcinosarcoma (UCS) tumor, the gene set of the transcriptional signature is gene set llll) or mmmm).
[0139] In some embodiments, the use of "short TEAD tag" does not include the use of gene sets q1), kkk1), ppp1), and qqq1).
[0140] In some embodiments, the uses as disclosed herein may include:
[0141] a) Measuring the expression level of each gene of the gene set of "TEAD tag" (i.e., any 220 to 249 genes (positive effect genes) of gene set (1) and any 210 to 233 genes (negative effect genes) of gene set (2)) in a biological sample of a cancer tumor,
[0142] b) For each gene in the gene set shown in Table 1, converting the expression level of the gene obtained in step a) into a fractional rank by dividing the rank of the gene by the number of genes of the gene set of "TEAD tag",
[0143] c) Multiplying each fractional rank obtained in step b) by the coefficient associated with each gene of the gene set in Table 1 to obtain a product for each gene, the coefficients and gene sets of the genes being shown in Table 2;
[0144] d) Summing the products obtained in step c) to obtain a discriminant score (S);
[0145] e) For the gene set of Table 1, comparing the discriminant score (S) obtained in step d) with the centroids of the TEAD-active (A) and TEAD-inactive (I) groups shown in Table 2;
[0146] f) Determining whether (S) is closer to (A) rather than (I) according to the formula max(S,A) - min(S,A) < max(S,I) - min(S,I); and
[0147] g) If (S) is closer to (A) rather than (I), then characterizing the sample as TEAD-active.
[0148] In some embodiments, the uses as disclosed herein may enable:
[0149] The cancer may be selected from adrenocortical carcinoma (ACC) tumors; bladder urothelial carcinoma (BLCA) tumors; invasive breast cancer (BRCA) tumors; BRCA basal tumors; BRCA non-basal tumors; cervical squamous cell carcinoma and cervical adenocarcinoma (CESC) tumors; bile duct carcinoma (CHOL) tumors; colon adenocarcinoma (COAD) tumors; COAD CMS1 tumors; COAD CMS4 tumors; lymphoid neoplasms diffuse large B-cell lymphoma (DLBC) tumors; esophageal carcinoma (ESCA) tumors; glioblastoma multiforme (GBM) tumors; head and neck squamous cell carcinoma (HNSC) tumors; kidney chromophobe carcinoma (KICH) tumors; kidney clear cell carcinoma (KIRC) tumors; kidney papillary cell carcinoma (KIRP) tumors; brain low grade glioma (LGG) tumors; hepatocellular carcinoma (LIHC) tumors; LIHCS1 tumors; LIHC S2 tumors; LIHC S3 tumors; lung adenocarcinoma (LUAD) tumors; lung squamous cell carcinoma (LUSC) tumors; LUSC basal tumors; LUSC classical tumors; LUSC primary tumors; LUSC secretory tumors; malignant mesothelioma (MESO) tumors; pancreatic adenocarcinoma (PAAD) tumors; rectal adenocarcinoma (READ) tumors; READ CMS1 tumors; READ CMS2 tumors; READ CMS4 tumors; sarcoma (SARC) tumors; cutaneous melanoma (SKCM) tumors; SKCM immune tumors; SKCM keratin tumors; STAD MSI tumors; STAD MSS_EMT tumors; testicular germ cell tumor (TGCT) tumors; endometrial carcinoma (UCEC) tumors; uterine carcinosarcoma (UCS) tumors,
[0150] and
[0151] Such uses may include:
[0152] a) measuring the expression level of each gene in a gene set associated with the tumor in a biological sample of a tumor of the cancer, wherein the gene set is selected from the group consisting of set a), set c), set d), set e), set g), set i), set j), set l), set m), set q), set r), set t), set v), set x), set y), set aa), set bb), set dd), set ff), set gg), set ii), set kk), set mm), set rr), set ss), set uu), set vv), set xx), set zz), set kkk), set lll), set mmm), set nnn), set ppp), set rrr), set sss), set ttt), set uuu), set zzz), set bbbb), set hhhh), set kkkk), and set llll);
[0153] b) for each gene in the gene set, converting the expression level of the gene obtained in step a) into a fractional rank by dividing the rank of the gene by the number of gene sets;
[0154] c) multiplying each score rank obtained in step b) by a coefficient associated with each gene of the gene set to obtain a product for each gene (P gene i ), the coefficients and gene sets of the genes are shown in Table 2;
[0155] d) determining a discriminant score (DS) of the gene set, wherein the discriminant score (DS) is the product P gene set obtained in step c). i The sum of the constant coefficients for the gene sets shown in Table 2,
[0156] e) for the gene set, comparing the discriminant score (DS) obtained in step d) with a threshold associated with the gene set to determine whether the cancer is TEAD-active or TEAD-inactive, the threshold being shown in Table 3. Table 3. Thresholds for determining TEAD status as tumor “active” or “inactive” for each group (indication or sub-indication) for the “short TEAD signature” NA: Not applicable
[0157] The use indicated above may be referred to as method 4.
[0158] In some embodiments, the biological sample can be blood, plasma, serum, cerebrospinal fluid (CSF), tissue, cells, or a tumor biopsy.
[0159] In some embodiments, the use may be for characterizing a subject as having a TEAD-active cancer or a TEAD-inactive cancer.
[0160] In some embodiments, the use may be for predicting whether a subject will have a positive response to a TEAD pathway inhibitor.
[0161] In some embodiments, a TEAD pathway inhibitor may be administered to the subject if the subject is characterized as having a TEAD-active cancer, or if the subject is predicted to be responsive to a TEAD pathway inhibitor.
[0162] In some embodiments, the disclosure relates to a method for characterizing TEAD activity of a cancer in a subject in need thereof, the method using a biological sample of a tumor of the cancer and comprising at least the following steps:
[0163] a) measuring the expression level of a gene in a transcriptome obtained from said biological sample,
[0164] b) for each gene in the gene set of the "TEAD signature" (i.e., any 220 to 249 genes of gene set (1) (positive effect genes) and any 210 to 233 genes of gene set (2) (negative effect genes)), converting the gene expression level obtained in step a) into a fractional rank by dividing the rank of the gene by the number of genes from the transcriptome,
[0165] c) separating the score ranks obtained for the genes of gene set (1) from the score ranks obtained in step b) and calculating their average score rank (MFR-positive),
[0166] d) separating the score ranks obtained for the genes of gene set (2) from the score ranks obtained in step b) and calculating their average score rank (MFR-negative), and
[0167] e) calculating the dgR score as MFR-positive-MFR-negative;
[0168] or
[0169] a) measuring the expression level of each gene of the “TEAD signature” gene set (i.e., any 220 to 249 genes (positive effector genes) of gene set (1) and any 210 to 233 genes (negative effector genes) of gene set (2)) in the biological sample,
[0170] b) for each gene of said gene set of "TEAD signature", converting the gene expression level obtained in step a) into a fractional rank by dividing the rank of said gene by the number of genes from said gene set,
[0171] c) separating the score ranks obtained for the genes of gene set (1) from the score ranks obtained in step b) and calculating their average score rank (MFR-positive),
[0172] d) separating the score ranks obtained for the genes of gene set (2) from the score ranks obtained in step b) and calculating their average score rank (MFR-negative),
[0173] e) calculating the deR score as MFR-positive-MFR-negative;
[0174] Wherein when the dgR or the deR score is greater than about 0.055, then the cancer is TEAD-active, and when the dgR or deR score is less than or equal to about 0.055, then the cancer is TEAD-inactive.
[0175] In some embodiments, the present disclosure relates to a method for characterizing TEAD activity of cancer in a subject in need thereof, the method using a biological sample of a tumor of the cancer and comprising at least the following steps:
[0176] a) Measuring the expression level of each gene of a "TEAD signature" gene set (i.e., any 220 to 249 genes (positive effector genes) of gene set (1) and any 210 to 233 genes (negative effector genes) of gene set (2)) in the biological sample;
[0177] b) For each gene in the gene sets shown in Table 1, converting the gene expression level obtained in step a) to a fractional rank by dividing the rank of the gene by the number of genes in the "TEAD signature" gene set;
[0178] c) Multiplying each fractional rank obtained in step b) by a coefficient associated with each gene in the gene sets in Table 1 to obtain a product for each gene, the coefficients and gene sets of the genes being shown in Table 2;
[0179] d) Summing the products obtained in step c) to obtain a discriminant score (S);
[0180] e) For the gene sets of Table 1, comparing the discriminant score (S) obtained in step d) with the centroids of the TEAD-active (A) and TEAD-inactive (I) groups shown in Table 2;
[0181] f) Determining whether (S) is closer to (A) than to (I) according to the formula max(S,A) - min(S,A) < max(S,I) - min(S,I); and
[0182] g) If (S) is closer to (A) than to (I), characterizing the cancer as TEAD-active.
[0183] In some embodiments, the present disclosure relates to a method for characterizing TEAD activity of cancer in a subject in need thereof, wherein
[0184] The cancer is selected from the group consisting of adrenocortical carcinoma (ACC) tumors; bladder urothelial carcinoma (BLCA) tumors; invasive breast cancer (BRCA) tumors; BRCA basal tumors; BRCA non-basal tumors; cervical squamous cell carcinoma and cervical adenocarcinoma (CESC) tumors; bile duct carcinoma (CHOL) tumors; colon adenocarcinoma (COAD) tumors; COAD CMS1 tumors; COAD CMS4 tumors; lymphoid neoplasms diffuse large B-cell lymphoma (DLBC) tumors; esophageal carcinoma (ESCA) tumors; glioblastoma multiforme (GBM) tumors; head and neck squamous cell carcinoma (HNSC) tumors; kidney chromophobe carcinoma (KICH) tumors; kidney clear cell carcinoma (KIRC) tumors; kidney papillary cell carcinoma (KIRP) tumors; brain low-grade glioma (LGG) tumors; hepatocellular carcinoma (LIHC) tumors; LIHC S1 tumors; LIHCS2 tumors; LIHC S3 tumors; lung adenocarcinoma (LUAD) tumors; lung squamous cell carcinoma (LUSC) tumors; LUSC basal tumors; LUSC classical tumors; LUSC primary tumors; LUSC secretory tumors; malignant mesothelioma (MESO) tumors; pancreatic adenocarcinoma (PAAD) tumors; rectal adenocarcinoma (READ) tumors; READ CMS1 tumors; READ CMS2 tumors; READ CMS4 tumors; sarcoma (SARC) tumors; cutaneous melanoma (SKCM) tumors; SKCM immune tumors; SKCM keratin tumors; STAD MSI tumors; STAD MSS_EMT tumors; testicular germ cell tumor (TGCT) tumors; endometrial carcinoma (UCEC) tumors; and uterine carcinosarcoma (UCS) tumors,
[0185] and
[0186] The method uses a biological sample of a tumor of the cancer, and
[0187] The method comprises at least the following steps:
[0188] a) measuring the expression level of each gene in a gene set associated with the tumor in a biological sample of the tumor, wherein the gene set is selected from the group consisting of set a), set c), set d), set e), set g), set i), set j), set l), set m), set q), set r), set t), set v), set x), set y), set aa), set bb), set dd), set ff), set gg), set ii), set kk), set mm), set rr), set ss), set uu), set vv), set xx), set zz), set kkk), set lll), set mmm), set nnn), set ppp), set rrr), set sss), set ttt), set uuu), set zzz), set bbbb), set hhhh), set kkkk), and set llll);
[0189] b) for each gene in the gene set, converting the expression level of the gene into a fractional rank by dividing the rank of the gene by the gene weight of the gene in the gene set;
[0190] c) multiplying each score rank obtained in step b) by a coefficient associated with each gene of the gene set to obtain a product for each gene (P gene i ), the coefficients and gene sets of the genes are shown in Table 2;
[0191] d) determining a discriminant score (DS) of the gene set, wherein the discriminant score (DS) is the product P gene set obtained in step c). i The sum plus the constant coefficient for the gene set shown in Table 2;
[0192] e) for the gene set, comparing the discriminant score (DS) obtained in step d) with a threshold associated with the gene set to determine whether the cancer is TEAD-active or TEAD-inactive, the threshold being shown in Table 3.
[0193] A kit comprising a solid support containing a set of nucleic acids for determining transcription of a gene set according to the present disclosure.
[0194] In some embodiments, the use or method may comprise detecting the RNA expression level of each gene in the panel.
[0195] In some embodiments, the use or method may comprise RNA sequencing.
[0196] In some embodiments, the present disclosure relates to a kit comprising a solid support comprising a nucleic acid biomarker panel as disclosed herein.
[0197] In some embodiments, the disclosure relates to a kit comprising a solid support comprising a set of nucleic acids for determining transcription of a gene set as disclosed herein. DETAILED DESCRIPTION definition
[0198] Tags, gene tags and transcription tags. As used herein, those terms and words mean the transcription pattern of the gene set that may be associated with TEAD active cancer or tumor. The transcription tag is obtained by measuring the expression level of the gene (or gene set of the tag) of the tag in the biological sample. In the biological sample, people can measure the expression level of all or part of the genes that are easy to express in the biological sample. When only some genes are measured, all genes of the target gene set must be measured at least.
[0199] Transcriptome. The term "transcriptome" is intended to refer to the collection of all transcript reads (RNA) (including coding and non-coding) of a single cell or cell population. In the present disclosure, a transcriptome can be used in whole or in part. When used in part, it must at least contain all genes of the target gene set.
[0200] Herein, "transcription" and "gene expression" are used interchangeably to refer to the production of RNA. The transcription or expression of a gene may be increased or decreased, resulting in an increase or decrease in RNA production.
[0201] Positive effectors. Positive effectors are genes whose transcript levels are positively correlated with TEAD activity. When the TEAD pathway is activated in some way, the positive effector increases, or when the TEAD pathway is inhibited, the positive effector decreases. Positive effectors are not necessarily expected to respond in both directions of TEAD regulation. For example, a gene with zero normal expression in a tissue may be observed to increase after TEAD activation, but it cannot be expected that the gene will decrease after TEAD inhibition. Even at higher normal expression levels, positive effector genes are not necessarily sensitive to both TEAD activation and inhibition.
[0202] Negative effectors. A negative effector is a gene whose transcript level is negatively correlated with TEAD activity. It decreases after TEAD activation or increases with TEAD inhibition. Like positive effectors, negative effectors are not necessarily expected to respond to TEAD regulation in both directions. For example, a gene with zero normal expression in a tissue may be observed to increase after TEAD pathway inhibition, but it cannot be expected that the gene will decrease after TEAD activation. Even at higher normal expression levels, a negative effector gene may be sensitive to TEAD activation, but not affected by TEAD inhibition, and vice versa.
[0203] TEAD-500 gene list. A list of the most significant positive or negative effectors regulated by 500 or fewer TEADs. These genes were selected by differential expression analysis of 18 published expression array data sets. Some of the 500 genes are direct targets of TEAD transcription factors, which means that they present TEAD recognition motifs in their promoters, but most of these 500 genes are subject to secondary or indirect regulation of the TEAD pathway. Due to technological development (from various commercial expression arrays to RNA sequencing technology), and also due to inconsistent gene naming, the group does not actually contain 500 genes, but now contains 482 genes. Therefore, in this disclosure, the group is referred to as "TEAD-500", but the TEAD-500 group consists of about 90% of 482 genes to 482 genes. Deletion of up to at least 10% only negligibly affects its score. This is one of the reasons why TEAD-500 is highly robust.
[0204] TEAD signature. As used herein, "TEAD signature" is intended to refer to a transcriptional signature obtained by measuring the gene expression levels of a gene set, the gene set including any 220 to 249 positive effect genes and any 210 to 233 negative effect genes as listed herein. By extension, depending on the context, a "TEAD signature" may refer to a related gene set.
[0205] Short TEAD signature. As used herein, "short TEAD signature" is intended to refer to a transcriptional signature obtained by measuring the gene expression levels of a gene set selected from set a) to mmmm of Table 1. By extension, depending on the context, a "short TEAD signature" may refer to a related gene set.
[0206] Scoring. The TEAD-500 score (referred to herein as "TEAD score") is a program for calculating the activity of the TEAD pathway in a sample on a continuous scale of values. The score is based on the average score rank of the transcript levels of positive effectors and negative effectors. Depending on the available data set, two types of scores can be calculated, referred to as dgR or deR. The two scores are not the same, but similar. They both draw the same conclusion, but their values are not comparable. They both represent the difference Rp-Rn, where Rp is the average score rank of the positive effectors, and Rn is the average score rank of the negative effectors. They differ in the way they are defined and calculated score ranks.
[0207] Fractional rank. In an array of values such as gene levels in a transcriptome, each value is replaced by its rank, where the minimum value takes rank 1. The fractional rank of each gene is equal to its rank divided by the number of genes in the array (maximum rank).
[0208] Difference of whole genome rank (dgR). TEAD pathway activity scores were calculated from the whole transcriptome. When the entire transcriptome is available, all transcript levels can be converted to fractional ranks (transcript levels divided by the level of the most abundant transcript observed in the sample), and the average ranks of positive and negative effectors are calculated from the transcript levels so converted.
[0209] The difference of effector level (deR). For very large groups, or when the full transcriptome data is not available, it may be convenient to only query the genes of the TEAD-500 list. For the above-mentioned dgR, the levels of 500 transcripts are converted into score levels, but the level of 500 level values is obviously different from the level of, for example, 20000 values in the whole transcriptome. Therefore, deR is different from dgR, but these two scores can be used in the same way.
[0210] Determine (classify) TEAD activity status. This is a binary conversion of the continuous deR or dgR score of TEAD activity to two discrete state values ("active" or "active"). In some embodiments, we set the deR threshold to 0.055 based on experience. This value is selected from experiments with human mesothelioma cell lines. We observed that cell lines with deR scores less than 0.055 did not respond to YAP1-siRNA treatment, and when YAP1 was knocked out in this way, cell lines with higher scores stopped growing. For different tissues or treatments, the threshold of response may be different. A score value of 0.055 corresponds approximately to the 88th percentile of the score observed in tumors of the TCGA group (all indications combined). If the deR score of TEAD-500 is greater than 0.055, TEAD is judged to be active, otherwise it is inactive.
[0211] Discriminant function. Typically, this is a linear combination of predictive pointers (in this case, effector genes) that separate two (in this example) or more classes of objects - each accompanied by a coefficient. Our objects are tumor samples, and the two categories are "active" or "inactive" TEAD phenotypes, as they are determined by TEAD activity determination based on the TEAD-500 transcriptome signature. The resulting non-redundant gene combination can be used as a linear classifier or for dimensionality reduction before later classification.
[0212] Discriminant score (S). The score of a sample for a discriminant function is calculated as the sum of the products of the predictor transcript levels (usually score ranks or other normalized measures) multiplied by the corresponding predictor coefficients. For example, if the discriminant function includes genes X, Y, and Z, and the coefficients are x, y, and z, respectively, then the discriminant score (S) of sample i for the function will be:
[0213] Si=(x*Xi)+(y*Yi)+(z*Zi)
[0214] where Xi, Yi and Zi are the levels of transcripts X, Y and Z in sample i, respectively.
[0215] Discriminant score (DS). The score of the sample for the best discriminant function is calculated as the sum of the products of the best discriminant functions of all discriminant genes plus the constant coefficient of the best discriminant function. For example, if the best discriminant function for the indication to which the sample belongs has 10 genes, we multiply the score rank of each gene by the corresponding discriminant coefficient (called loading) of the gene, and we add the resulting product to the constant coefficient of the best discriminant function.
[0216] Discrimination score (DS) = Σ(gene i Score level*Gene i coefficient) + discriminant constant, where genei are the genes listed in the best discriminant function.
[0217] The best discriminant function for each of the gene sets a) to mmmm) is given. Each gene set is associated with a specific cancer type.
[0218] Group centroid. Referred to as the centroid, this is the average score of the discriminant function of a group of samples. In some embodiments, in order to classify samples as TEAD-active or TEAD-inactive, the centroid of each group is calculated as the average discriminant score within the group. The farther away from the average, the smaller the error during classification. Each new sample is classified according to the distance between its discriminant score and the two centroids. If its distance from the TEAD-active centroid is shorter than its distance from the TEAD-inactive centroid, the new sample is classified as TEAD-active, otherwise it is classified as TEAD-inactive.
[0219] Best discriminant function. By default, all significant predictors are used in the discriminant function. Using more than one alternative predictor can improve the robustness of the model by allowing deletions without affecting prediction accuracy. Unless otherwise indicated as minimal, the general term discriminant function in this article refers to the best solution.
[0220] Minimum Discriminant Function. For economic analysis, it may be desirable to retain only those predictors necessary to achieve 100% accuracy in classification. When the best discriminant function achieves 100% correct classification, predictors can be manually removed and stopped until accuracy drops below 100%. The minimum discriminant function is meaningful and reported in this paper only when the best solution achieves 100% correct classification.
[0221] TEAD pathway inhibitors. As used herein, a TEAD pathway inhibitor is any small molecule compound or macromolecular compound that inhibits the HIPPO-YAP / WWTR1 / TEAD pathway.
[0222] Expression level. As used herein, the "expression level" of a gene refers to the level of RNA expressed by any given gene. GENE PANEL and transcriptional signatures
[0223] In some embodiments, a panel of N nucleic acid biomarkers is contemplated, wherein N is an integer of at least 160 and less than or equal to 482, and wherein the N biomarkers include nucleic acids capable of detecting any 80 to 249 genes (positive effector genes) of the following gene set (1): AASS, ABAT, ACAT2, ADAMTS1, ADM, ADRB2, AMOT, ANXA3, ARHGAP11A, ARHGDIB, AURKB, AVPI1, AXL, AZIN1, B4GALT4, BCAT1, BIRC5, BTG3, C4BPB, CAP2, CAV1, CAVIN1, CCBE1, CCDC80, CCN1, CCN2, CDC25A, CDC6, CDCA3, CDCA4, CDCA5, CDCA8, CDH4, CDK2, CDK6, CDV3, CENPA, CENPI, CENPM, CENPN, CHRNB1, CHST13, CKS2, CLDN1, CLIC3, CNN 3. COBL, COL8A1, COTL1, CPA4, CRIM1, CRY1, CTH, CXCL1, CYTH3, DAPK1, DCLRE1B, DDAH1, DHCR7, DHFR, DIAPH3, DKK1, DLL1, DONSON, DUSP14, DUT, EBP, EIF 2AK3, EMG1, EPHA2, EPS8L2, ESM1, ETS1, EXO1, EXOSC2, F3, FAHD2A, FAM83D, FANCA, FAT4, FDPS, FEN1, FMR1, FST, FSTL1, FSTL3, GADD45A, GADD45B, GINS 1. GPC6, GPR176, GPRC5A, GPRC5B, GRAMD2B, HASPIN, HEG1, HEXB, HPS5, HSPB11, IDI1, IGFBP7, IKBIP, IL6, ITGB2, JDP2, JPH2, KPNA2, KRT8, KRT80, LCA5, LHFPL6, LMCD1, LMNB2, LRP8, LRRFIP2, LSM5, LYPD6, LYRM1, MAD2L1, MAP6D1, MATN2, MATN3, MCM10, MCM2, MCM5, MDC1, METRNL, MICB, MID1, MRPL33, MSRB 3. MVD, MXRA7, NCAPD3, NEDD4, NEDD4L, NEK2, NEXN, NFIB, NNMT, NOC3L, NTN4, NUAK1, NUAK2, NUDCD1, NUP107, NUP37, OGFRL1, OLFML3, OLR1, OXCT1, PAK2,PCBD1, PCNA, PDLIM2, PDZD2, PEPD, PHLPP1, PKMYT1, PKP2, PKP4, PLCE1, PLEKHA7, PLK2, PLOD2, PPIH, PRPS1, PRPS2, PRSS23, PSG2, PSG6, PSG7, PSG9, PVR, PXMP2, QDPR, QKI, RAB11FIP1, R AB32, RACGAP1, RBM24, RBMS2, RCN2, RFC4, RND3, RNF144B, ROR1, RPS24, SCD5, SCML1, SDC2, S EC14L1, SGK1, SGMS2, SGTB, SH3RF1, SHCBP1, SKP2, SLC25A23, SLC25A3, SLC38A5, SLC3A2, SLC 7A1, SLC7A5, SMPD4, SNAPC1, SNX24, SORT1, SPAG1, SPATA5, STK3, STX11, STXBP6, SUSD2, SUV39H1, SYDE2, TACC3, TAGLN, TEAD1, TEAD4, TENT5B, TGM2, THBS1, TK1, TMEM139, TMEM160, TNFAIP3, TNFRSF12A, TNNC1, TPM1, TPX2, TRIP13, TSPAN2, TTF2, TUBB6, TUFT1, TYMS, UAP1, UBE2C, UGCG, UHRF1, VKORC1L1, WWC1, WWC2, YAP1, ZBED2, ZDHHC18, ZNF488, and ZNF704 (“positive effector genes”); and
[0224] Any 80 to 233 genes (negative effect genes) from the following gene sets (2): AASDH, ABCA1, ABCC5, ABI3BP, ABLIM3, ACADVL, ACOT11, ACOX2, ACSL5, ADAM28, AGL, AGPAT4, ALDH3A2, ANKRD12, ANKRD22, ANKRD29, ANKRD42, ANTXR2, APBB3, ARAP3, ARHGEF2, ASF1A, ATP7A, ATXN1, BCL11B, BHLHE41, BMF, CA2, CASP1, CBR3, CCNG2, CDC42EP4, CDK1, CEBPB, C ELSR3, CLCN3, CLDN4, COL6A1, COL6A2, CPE, CRABP2, CROT, CSRNP2, CSTA, CTNNBIP1, CTSB, CTSK, CXXC5, CYP1B1, CYP27C1, DDR1, DEDD2, DHX32, DIAPH2, D SC2, DSG3, DUSP6, DYNC2LI1, ELN, EPS8L3, ERAP2, FAM102A, FAM117B, FAM83B, FAM89B, FERMT1, FKBP2, FOS, FTH1, FXYD3, GDPD1, GOLGA5, GOLPH3L, GPNMB , GPRC5C, GRB10, GSN, HAS3, HBP1, HDAC1, HDHD2, HEY1, HOXA5, IFI44, IGSF3, IGSF9, INTS3, IRAK2, IRF9, IRX5, ITGA2, KCNMA1, KCNMB3, KCNN4, KIFAP3, K LF10, KLF13, KLHL3, KLK11, KRCC1, KRIT1, KRTDAP, LMTK3, LRP10, LTBP4, LXN, LYPD3, MALL, MANSC1, MAPK13, MARCKSL1, MFSD1, MFSD5, MGST2, MGST3, MLL T11, MLPH, MMP13, MSX2, MTMR11, MTMR9, MTSS1, MYO1A, NAGK, NAPEPLD, NCOA3, NFIL3, NPAS2, NRIP1, OAS1, OAS2, OASL, OFD1, OSBPL7, OTUB2, OVOL1, PAG1 , PAK1, PCDHB2, PCDHB9, PCGF3, PCMTD2, PERP, PHF21A, PIK3C2B, PIK3R1, PIK3R2, PIK3R3, PIP4P2, PJA2, PKIA, PLA2G4C, PNRC1, PPP1R11, PRRX2, PTPRE,PYGB, RAC2, RALGPS1, RAPGEFL1, RBM23, RBM45, RBM47, RBP1, REEP6, RGL2, RGS17, RHOC, S100A14, SAMD9, SEC14L2, SECISBP2, SH3PXD2A, SH3TC1, SHROOM2, SLC14A1, SLC1A2, SLC30A9, SLC35C1, SLC37A2, SLC39A11, SLFN5, SLITRK6, SLK, SMOC1, SNCG, SP1, SPIRE2, SPRY4, SQSTM1, SRD5A3, SSPN, STMN3, STX1A, TB X3, TCF25, TDO2, TET2, TFF1, TLR3, TMC4, TMC7, TMEM140, TMEM144, TMEM45B, TP53INP1, TP63, TPD52L1, TRAPPC6B, TRIB1, TRIB2, TRIM13, TRIM31, TRIM38, TRIOBP, TRIP11, TSC22D1, TSPAN1, TTC17, TTLL3, TUBB3, UBC, ULK1, VAMP8, VGF, VPS52, VSNL1, WDR13, ZCWPW1, ZNF292, ZNF467, ZNF75D, and ZSWIM7 (“negative effector genes”).
[0225] In some embodiments, a panel of N nucleic acid biomarkers is contemplated, wherein the N biomarkers include nucleic acids capable of detecting at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58 , at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65, at least 66, at least 67, at least 68, at least 69, at least 70, at least 71, at least 72, at least 73, at least 74, at least 75, at least 76, at least 77, at least 78, at least 79, at least 80, 109, at least 110, at least 111, at least 112, at least 113, at least 114, at least 115, at least 116, at least 117, at least 118, at least 119, at least 120, at least 121, at least 122, at least 123, at least 124, at least 125, at least 126, at least 127, at least 128, at least 129, at least 130, at least 131, at least 132, at least 133, at least 134, at least 135, at least 136, at least 137, at least 138, at least 139, at least 140, at least 141, at least 142, at least 143, at least 144, at least 145, at least 146, at least 147, at least 148 149, at least 150, at least 151, at least 152, at least 153, at least 154, at least 155, at least 156, at least 157, at least 158, at least 159, at least 160, at least 161, at least 162, at least 163, at least 164, at least 165, at least 166, at least 167, at least 168, at least 169, at least 170, at least 171, at least 172, at least 173, at least 174, at least 175, at least 176, at least 177,at least 154, at least 155, at least 156, at least 157, at least 158, at least 159, at least 160, at least 161, at least 162, at least 163, at least 164, at least 165, at least 166, at least 167, at least 168, at least 169, at least 170, at least 171, at least 172, at least 173, at least 174, at least 175, at least 176, at least 177, at least 178, at least 179, at least 180, at least 181, at least 182, at least 183, at least 184, at least 185, at least 186, at least 187, at least 188, at least 189, at least 190, at least 191, at least 192, at least 193, at least 194, at least 195, at least 196, at least 197, at least 198, at least 199, at least 200, at least 201, at least 202 , at least 203, at least 204, at least 205, at least 206, at least 207, at least 208, at least 209, at least 210, at least 211, at least 212, at least 213, at least 214, at least 215, at least 216, at least 217, at least 218, at least 219, at least 220, at least 221, at least 222, at least 223, at least 224, at least 225, at least 226, at least 227, at least 227, at least 228, at least 229, at least 230, at least 231, at least 232, at least 233, at least 234, at least 235, at least 236, at least 237, at least 238, at least 239, at least 240, at least 241, at least 242, at least 243, at least 244, at least 245, at least 246, at least 247, at least 248 or all 249 genes (positive effect genes), and,
[0226] The invention also includes nucleic acids capable of detecting at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, at least 20, at least 21, at least 22, at least 23, at least 24, at least 25, at least 26, at least 27, at least 28, at least 29, at least 30, at least 31, at least 32, at least 33, at least 34, at least 35, at least 36, at least 37, at least 38, at least 39, at least 40, at least 41, at least 42, at least 43, at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55 , at least 44, at least 45, at least 46, at least 47, at least 48, at least 49, at least 50, at least 51, at least 52, at least 53, at least 54, at least 55, at least 56, at least 57, at least 58, at least 59, at least 60, at least 61, at least 62, at least 63, at least 64, at least 65, at least 66, at least 67, at least 68, at least 69, at least 70, at least 71, at least 72, at least 73, at least 74, at least 75, at least 76, at least 77, at least 78, at least 79, at least 80, at least 81, at least 82, at least 83, at least 84, at least 109, at least 110, at least 111, at least 112, at least 113, at least 114, at least 115, at least 116, at least 117, at least 118, at least 119, at least 120, at least 121, at least 122, at least 123, at least 124, at least 125, at least 126, at least 127, at least 128, at least 129, at least 130, at least 131, at least 132, at least 133, at least 134, at least 135, at least 136, at least 137, at least 138, at least 139, at least 140, at least 141, at least 142, at least 143, at least 144, at least 145 147, at least 148, at least 149, at least 150, at least 151, at least 152, at least 153, at least 154, at least 155, at least 156, at least 157, at least 158, at least 159, at least 160, at least 161, at least 162, at least 163, at least 164, at least 165, at least 166, at least 167, at least 168, at least 169, at least 170, at least 171, at least 172, at least 173, at least 174, at least 175, at least 176, at least 177, at least 178, at least 179, at least 180,189, at least 190, at least 191, at least 192, at least 193, at least 194, at least 195, at least 196, at least 197, at least 198, at least 199, at least 100, at least 101, at least 102, at least 103, at least 104, at least 105, at least 106, at least 107, at least 108, at least 109, at least 110, at least 111, at least 112, at least 113, at least 114, at least 115, at least 116, at least 117, at least 197, at least 198, at least 199, at least 200, at least 201, at least 202, at least 203, at least 204, at least 205, at least 206, at least 207, at least 208, at least 209, at least 210, at least 211, at least 212, at least 213, at least 214, at least 215, at least 216, at least 217, at least 218, at least 219, at least 220, at least 221, at least 222, at least 223, at least 224, at least 225, at least 226, at least 227, at least 228, at least 229, at least 230, at least 231, at least 232, or all 233 genes (negative effect genes).
[0227] In some embodiments, a panel of nucleic acid biomarkers is contemplated, wherein N is an integer of at least 10 and less than or equal to 482, and wherein the N biomarkers include nucleic acids capable of detecting any 10 to 249, 20 to 249, 30 to 249, 40 to 249, 50 to 249, 60 to 249, 70 to 249, 80 to 249, 90 to 249, 49, 100-249, 110-249, 120-249, 130-249, 140-249, 150-249, 160-249, 170-249, 180-249, 190-249, 200-249, 210-249, 220-249, 230-249 or 240-249 genes (positive effector genes); and
[0228] any 10 to 233, 20 to 233, 30 to 233, 40 to 233, 50 to 233, 60 to 233, 70 to 233, 80 to 233, 90 to 233, 100 to 233, 110 to 233, 120 to 233, 130 to 233, 140 to 233, 150 to 233, 160 to 233, 170 to 233, 180 to 233, 190 to 233, 200 to 233, 210 to 233, 220 to 233 or 230 to 233 genes of gene set (2) (negative effector genes).
[0229] In some embodiments, the panel includes nucleic acid biomarkers capable of detecting about 90% of the 482 genes (positive and negative effector genes) of gene sets (1) and (2). In some embodiments, the panel includes nucleic acid biomarkers capable of detecting 430, 431, 432, 433, 434, 436, or 437 genes.
[0230] In some embodiments, the panel includes nucleic acid biomarkers capable of detecting the expression level of each gene within any one of the following gene sets a) to mmmm).
[0231] In some embodiments, the panel includes nucleic acid biomarkers capable of detecting the expression level of each gene within any of the following gene sets a) to mmmm) (excluding gene sets q1), kkk1), ppp1), and qqq1).
[0232] A transcriptional signature ("TEAD signature") can be obtained by measuring the expression levels of genes of a gene set, the gene set comprising any 220 to 249 genes of gene set (1) (positive effect genes) and any 210 to 233 genes of gene set (2) (negative effect genes) as indicated above.
[0233] The transcriptional signature ("TEAD signature") can be obtained by measuring the expression levels of genes of a gene set, wherein the gene set includes any 220 to 249 genes (positive effector genes) of gene set (1), or any 225 to 249, or any 230 to 249, or any 235 to 249, or any 240 to 249, or any 245 to 249 genes (positive effector genes) of gene set (1).
[0234] The transcriptional signature ("TEAD signature") can be obtained by measuring the expression levels of genes in a gene set, wherein the gene set includes any 210 to 233 genes (negative effect genes) of gene set (2), or any 215 to 233, or any 220 to 233, or any 225 to 233, or any 230 to 233 genes (negative effect genes) of gene set (2).
[0235] A transcriptional signature ("TEAD signature") can be obtained by measuring the expression levels of genes of a gene set including any 430 to 482 genes indicated above, or any 435 to 482, or any 440 to 482, or any 445 to 482, or any 450 to 482, or any 455 to 482, or any 460 to 482, or any 465 to 482, or any 470 to 482, or any 475 to 482, or any 480 to 482 genes indicated above.
[0236] A transcriptional signature ("TEAD signature") can be obtained by measuring the expression levels of genes of a gene set, the gene set comprising any 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442, 443, 444, 445, 446, 447, 448, 449, 450, 451 indicated above. , 452, 453, 454, 455, 456, 457, 458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481 or 482 genes.
[0237] The transcriptional signature ("TEAD signature") can be used to calculate a TEAD score according to method 1 or method 2 as disclosed above. Depending on the method used, the TEAD score can be a dgR or deR score. A dgR or deR score greater than about 0.055 indicates a TEAD active cancer. A dgR or deR score less than about 0.055 indicates a TEAD inactive cancer.
[0238] In some embodiments, the transcriptional tags can be reduced to shorter tags. Those shorter tags are referred to below as "short TEAD tags".
[0239] The "short TEAD signature" is obtained by measuring the gene expression levels of a reduced number of genes and is specific to a given cancer type.
[0240] In some embodiments, the present disclosure relates to the use of a transcriptional signature ("short TEAD signature") for measuring TEAD activity in a cancer in a subject in need thereof, wherein the transcriptional signature is obtained by measuring the expression levels of genes of a gene set in a biological sample of a tumor of the cancer, wherein the gene set is selected from set a) to mmmm) as disclosed in Table 1 or Table 2 above.
[0241] Each gene set is selective for analyzing a specific cancer type / subtype, as described in embodiments 3-59 of Tables 1 and 2.
[0242] The short TEAD tag can be used to calculate the discrimination score (S) or (DS) according to Method 3 or Method 4.
[0243] In method 3, the discriminant score (S) is compared to the centroids of the TEAD active (A) and TEAD inactive (I) groups provided for each cancer indication or subtype associated with a gene set from gene sets a) to mmmm) as shown in Tables 1 and 2. If (S) is closer to (A) than to (I), the sample is classified as TEAD active. Otherwise, the sample is classified as TEAD inactive.
[0244] In some embodiments, in this method, the use of a "short TEAD signature" does not include the use of gene sets q1), kkk1), ppp1), and qqq1).
[0245] In method 4, the discriminant score (DS) is compared to the thresholds from those shown in Table 6 and correlated to the cancer indication or subtype associated with the gene set of gene sets a) to mmmm) to determine whether the cancer is TEAD-active or TEAD-inactive. Methods and uses
[0246] Provided are methods and uses utilizing the group, including measuring TEAD-dependent transcriptional levels, characterizing subjects as having TEAD-active cancer or TEAD-inactive cancer, and predicting whether subjects are likely to have a positive response to TEAD pathway inhibitors. The method includes separating biological samples from subjects suffering from or suspected of having cancer (solid or blood), detecting the expression level of each gene, and scoring the one or more groups according to the methods described herein, wherein the method differs according to the use of the best / minimum discriminant function of the TEAD-500 group or the TEAD-500 subset group. In some embodiments, the method / use further includes an active step of administering a TEAD pathway inhibitor to a subject identified by using the disclosed group. In some embodiments, the step of isolating the biological sample is not part of the method and is performed before implementing the method.
[0247] In some embodiments, the transcriptional signature ("TEAD signature" or "short TEAD signature") can be used to determine, measure or characterize TEAD activity of a tumor of a cancer. The transcriptional signature can be used for a variety of applications, including predicting the likelihood that a subject will respond to treatment with a TEAD pathway inhibitor, selecting patients for clinical trials, evaluating the efficacy of TEAD pathway inhibitor molecules, and predicting survival under anti-TEAD pathway treatment, response to the treatment, and benefit from the treatment.
[0248] In some embodiments, a transcriptional signature ("TEAD signature" or "short TEAD signature") can be obtained by measuring the TEAD-dependent transcriptional levels of genes in a biological sample from a subject having or suspected of having cancer. The genes can be from a gene set of the present disclosure.
[0249] The use comprises detecting or measuring the expression level of each gene of the gene set of the signature in a biological sample obtained from a subject in need thereof. The biological sample is isolated from a tumor present in the subject.
[0250] In some embodiments, a transcriptional signature ("TEAD signature" or "short TEAD signature") can be used to characterize a subject as having a TEAD-active cancer or a TEAD-inactive cancer.
[0251] The use includes detecting or measuring the expression level of each gene of the gene set of the signature in a biological sample obtained from a subject suffering from or suspected of suffering from cancer.
[0252] Depending on the situation, the transcriptional signature can be used to calculate the TEAD score dgR (method 1) or deR (method 2) or the discriminant score (S) (method 3) or (DS) (method 4).
[0253] If the dgR or deR obtained with the "TEAD Signature" is greater than about 0.055, the subject is considered to have a TEAD-active cancer.
[0254] If the discriminant score (DS) obtained with the "short TEAD signature" is closer to the centroid of the TEAD-active (A) group than to the centroid of the TEAD-inactive (I) group, the subject is considered to have a TEAD-active cancer.
[0255] If the discriminant score (S) obtained with the "short TEAD signature" is above or below the threshold value given in Table 3 (as appropriate), the subject is considered to have a TEAD-active cancer.
[0256] In some embodiments, a transcriptional signature ("TEAD signature" or "short TEAD signature") can be used to predict whether a subject will respond positively to a TEAD pathway inhibitor.
[0257] If the dgR or deR obtained using the "TEAD signature" is greater than about 0.055, then the subject is considered likely to respond positively to a TEAD pathway inhibitor.
[0258] If the discrimination score (DS) obtained with the "short TEAD signature" is closer to the centroid of the TEAD active (A) group than to the centroid of the TEAD inactive (I) group, the subject is considered to have a positive response to the TEAD pathway inhibitor.
[0259] If the discrimination score (S) obtained with the "short TEAD signature" is above or below the threshold value given in Table 3 (as appropriate), the subject is considered likely to respond positively to a TEAD pathway inhibitor.
[0260] In some embodiments comprising the use of the TEAD-500 panel, after the genes on the TEAD-500 panel are detected and gene expression is calculated, a TEAD score is provided as described above in Method 1 or Method 2. If the dgR or deR is greater than about 0.055, the subject is referred to as having a TEAD-active cancer, and if the dgR or deR is less than or equal to about 0.055, the subject is referred to as having a TEAD-inactive cancer. Similarly, if the dgR or deR is greater than about 0.055, the subject may be positively responsive to a TEAD pathway inhibitor, and if the dgR or deR is less than or equal to about 0.055, the subject may be unresponsive to a TEAD pathway inhibitor.
[0261] In some embodiments, a group of gene sets a) to mmmm) is provided for use in any of method 3 or method 4 described herein, any of which comprises measuring TEAD-dependent transcription levels, characterizing a subject as having a TEAD-active cancer or a TEAD-inactive cancer, or predicting whether a subject will respond positively to a TEAD pathway inhibitor, wherein the group comprises any one of the gene subsets of embodiments 3 to 59 above.
[0262] This method 3 includes the following steps: i) determining the expression level of each gene in the set; ii) determining the fractional rank of each gene; iii) multiplying the fractional rank of each gene by the corresponding coefficient shown in parentheses for each gene in each group; iv) summing the products to give a discriminant score (S); v) comparing the discriminant score (S) with the centroids of the TEAD-active (A) and TEAD-inactive (I) groups; vi) determining whether S is closer to (A) rather than (I) according to the formula max(S,A) - min(S,A) < max(S,I) - min(S,I); and vii) if (S) is closer to (A) rather than (I), characterizing the sample as TEAD-active, and if (S) is closer to (I) rather than (A), characterizing the sample as TEAD-inactive.
[0263] In some embodiments, method 3 may include the following steps: i) measuring the expression level of each gene in a gene set of "TEAD tags" (i.e., any 220 to 249 genes (positive effector genes) of gene set (1) and any 210 to 233 genes (negative effector genes) of gene set (2)) in a biological sample; ii) for each gene of the gene set shown in Table 1, converting the gene expression level obtained in step i) to a fractional rank by dividing the rank of the gene by the gene mass of the gene set of the "TEAD tags"; iii) multiplying each fractional rank obtained in step iii) by the coefficient associated with each gene of the gene set in Table 1 to obtain a product for each gene, the coefficient and gene set of the gene being shown in Table 2; iv) summing the products to obtain a discriminant score (S); v) comparing the discriminant score (S) with the centroids of the TEAD-active (A) and TEAD-inactive (I) groups for the gene set described in Table 1 shown in Table 2; vi) determining whether (S) is closer to (A) rather than (I) according to the formula max(S,A) - min(S,A) < max(S,I) - min(S,I); and vii) if (S) is closer to (A) rather than (I), characterizing the sample as TEAD-active, and if (S) is closer to (I) rather than (A), characterizing the sample as TEAD-inactive.
[0264] In some embodiments, method 3 does not include using gene sets q1), kkk1), ppp1), and qqq1).
[0265] The method 4 includes:
[0266] (i) for the indication to which the tumor belongs, the expression levels of the genes listed in the best discriminant functions of Set a), Set c), Set d), Set e), Set g), Set i), Set j), Set l), Set m), Set q), Set r), Set t), Set v), Set x), Set y), Set aa), Set bb), Set dd), Set ff), Set gg), Set ii), Set kk), Set mm), Set rr), Set ss), Set uu), Set vv), Set xx), Set zz), Set kkk), Set lll), Set mmm), Set nnn), Set ppp), Set rrr), Set sss), Set ttt), Set uuu), Set zzz), Set bbbb), Set hhhh), Set kkkk) and Set llll) of Table 1 are determined (as indicated in Table 2). The expression levels can be determined by RNA sequencing, RT-qPCR or any other reliable method;
[0267] (ii) for each gene in the gene set, converting the expression level of the gene into a fractional rank, which, as defined herein, is the rank of the gene (i.e., the expression of the gene with respect to all genes is tested, where the gene with the lowest expression level is assigned a rank of 1, the gene with the second highest expression level is assigned a rank of 2, and so on, until the highest expressed gene is assigned the highest rank; equal expression levels are assigned an average rank, e.g., two genes with zero expression are assigned a rank of 1.5) divided by the number of genes in the gene set;
[0268] (iii) multiplying each score rank obtained in step (ii) by a coefficient associated with each gene in the gene set to obtain a product for each gene (P gene i ), the coefficients and gene sets of the genes are shown in Table 2;
[0269] (iv) The discriminant score (DS) of the gene set for the tumor sample is calculated as the sum of the product of all discriminant genes plus the constant coefficient of the discriminant function (i.e., the constant coefficient of the gene set shown in Table 2). For example, if the best discriminant function for the indication to which the sample belongs has 10 genes, we multiply the score rank of each gene by the corresponding discriminant coefficient of the gene (called loading), and we add the resulting product to the constant coefficient of the best discriminant function.
[0270] Discriminant score = Σ(score rank of gene i * coefficient of gene i) + discriminant constant, where gene i is the gene listed in the discriminant function;
[0271] and (v) determining the TEAD activity status of the sample using the threshold values for each indication as listed in Table 3.
[0272] In some embodiments, the method 4 may:
[0273] - when the cancer is selected from the group consisting of: adrenocortical carcinoma (ACC) tumors; bladder urothelial carcinoma (BLCA) tumors; invasive breast cancer (BRCA) tumors; BRCA basal tumors; BRCA non-basal tumors; cervical squamous cell carcinoma and cervical adenocarcinoma (CESC) tumors; bile duct carcinoma (CHOL) tumors; colon adenocarcinoma (COAD) tumors; COAD CMS1 tumors; COADCMS4 tumors; lymphoid neoplasms diffuse large B-cell lymphoma (DLBC) tumors; esophageal carcinoma (ESCA) tumors; glioblastoma multiforme (GBM) tumors; head and neck squamous cell carcinoma (HNSC) tumors; kidney chromophobe cell carcinoma (KICH) tumors; kidney clear cell carcinoma (KIRC) tumors; kidney papillary cell carcinoma (KIRP) tumors; brain low grade glioma (LGG) tumors; hepatocellular carcinoma (LIHC) tumors; LIHC S1 tumors; LIHC S2 tumors; LIHC S3 tumors; lung adenocarcinoma (LUAD) tumors; lung squamous cell carcinoma (LUSC) tumors; LUSC basal tumors; LUSC classical tumors; LUSC primary tumors; LUSC secretory tumors; malignant mesothelioma (MESO) tumors; pancreatic adenocarcinoma (PAAD) tumors; rectal adenocarcinoma (READ) tumors; READ CMS1 tumors; READ CMS2 tumors; READ CMS4 tumors; sarcoma (SARC) tumors; cutaneous melanoma (SKCM) tumors; SKCM immune tumors; SKCM keratin tumors; STAD MSI tumors; STAD MSS_EMT tumors; testicular germ cell tumor (TGCT) tumors; endometrial carcinoma (UCEC) tumors; and uterine carcinosarcoma (UCS) tumors,
[0274] and
[0275] -include:
[0276] a) measuring the expression level of each gene in a gene set associated with the tumor in a biological sample of a tumor of the cancer, wherein the gene set is selected from the group consisting of set a), set c), set d), set e), set g), set i), set j), set l), set m), set q), set r), set t), set v), set x), set y), set aa), set bb), set dd), set ff), set gg), set ii), set kk), set mm), set rr), set ss), set uu), set vv), set xx), set zz), set kkk), set lll), set mmm), set nnn), set ppp), set rrr), set sss), set ttt), set uuu), set zzz), set bbbb), set hhhh), set kkkk), and set llll);
[0277] b) for each gene in the gene set, converting the expression level of the gene obtained in step a) into a fractional rank by dividing the rank of the gene by the number of gene sets;
[0278] c) multiplying each score rank obtained in step b) by a coefficient associated with each gene of the gene set to obtain a product for each gene (P gene i ), the coefficients and gene sets of the genes are shown in Table 2;
[0279] d) determining a discriminant score (DS) of the gene set, wherein the discriminant score (DS) is the product P gene set obtained in step c). i The sum of the constant coefficients for the gene sets shown in Table 2,
[0280] e) for the gene set, comparing the discriminant score (DS) obtained in step d) with a threshold associated with the gene set to determine whether the cancer is TEAD-active or TEAD-inactive, the threshold being shown in Table 3.
[0281] In some embodiments, methods and uses utilizing TEAD-500 or any subset group of embodiments 3 to 59 (disclosed in Tables 1 and 2) are provided for monitoring the activity of a TEAD complex, evaluating the pharmacodynamics of an inhibitor of the TEAD pathway in vitro or in vivo, diagnosing a tumor whose progression or evolution is attributed to TEAD complex activation, enrolling patients with TEAD activity in clinical trials designed to evaluate TEAD pathway inhibitors, predicting survival, response to, and benefit from an anti-TEAD pathway therapy (e.g., treatment with a TEAD pathway inhibitor) alone or in combination with other therapies, estimating the proportion of cases in a cohort in which TEAD-dependent transcription may be responsible for tumor development or progression to become resistant to treatment, or measuring TEAD-dependent transcription in any tissue in the context of any condition, pathological or non-pathological, in the laboratory or clinic.
[0282] In some embodiments, the methods and uses of the present disclosure do not include the use of gene sets q1), kkk1), ppp1), and qqq1).
[0283] In some embodiments, the present disclosure relates to a method for measuring a transcriptional signature ("TEAD signature" or "short TEAD signature") in a biological sample from a subject having or suspected of having cancer, the method comprising a step of detecting or measuring the expression level of each gene of a gene set of the transcriptional signature ("TEAD signature" or "short TEAD signature") in the biological sample.
[0284] In some embodiments, the disclosure relates to a method for characterizing TEAD activity of a cancer in a subject in need thereof, the method using a biological sample of a tumor of the cancer and comprising at least the following steps:
[0285] a) measuring the expression level of a gene in a transcriptome obtained from said biological sample,
[0286] b) for each gene in the gene set of the "TEAD signature" (i.e., any 220 to 249 genes of gene set (1) (positive effect genes) and any 210 to 233 genes of gene set (2) (negative effect genes)), converting the gene expression level obtained in step a) into a fractional rank by dividing the rank of the gene by the number of genes from the transcriptome,
[0287] c) separating the score ranks obtained for the genes of gene set (1) from the score ranks obtained in step b) and calculating their average score rank (MFR-positive),
[0288] d) separating the score ranks obtained for the genes of gene set (2) from the score ranks obtained in step b) and calculating their average score rank (MFR-negative), and
[0289] e) calculating the dgR score as MFR-positive-MFR-negative;
[0290] or
[0291] a) measuring the expression level of each gene of the “TEAD signature” gene set (i.e., any 220 to 249 genes (positive effector genes) of gene set (1) and any 210 to 233 genes (negative effector genes) of gene set (2)) in the biological sample,
[0292] b) for each gene of the gene set of the "TEAD signature" (i.e., any 220 to 249 genes of gene set (1) (positive effect genes) and any 210 to 233 genes of gene set (2) (negative effect genes)), converting the gene expression level obtained in step a) into a fractional rank by dividing the rank of the gene by the number of genes from the gene set,
[0293] c) separating the score ranks obtained for the genes of gene set (1) from the score ranks obtained in step b) and calculating their average score rank (MFR-positive),
[0294] d) separating the score ranks obtained for the genes of gene set (2) from the score ranks obtained in step b) and calculating their average score rank (MFR-negative),
[0295] e) Calculate the deR score as MFR - positive - MFR - negative;
[0296] Wherein when the dgR or the deR score is greater than about 0.055, then the cancer is TEAD - active, and when the dgR or deR score is less than or equal to about 0.055, then the cancer is TEAD - inactive.
[0297] In some embodiments, the present disclosure relates to a method for characterizing the TEAD - activity of a cancer in a subject in need thereof, the method using a biological sample of a tumor of the cancer and comprising at least the following steps:
[0298] a) Measure the expression level of each gene of a "TEAD - tag" gene set (i.e., any 220 to 249 genes (positive - effect genes) of gene set (1) and any 210 to 233 genes (negative - effect genes) of gene set (2)) in the biological sample,
[0299] b) For each gene in the gene sets shown in Table 1, convert the gene expression level obtained in step a) to a fractional rank by dividing the rank of the gene by the number of genes in the "TEAD - tag" gene set,
[0300] c) Multiply each fractional rank obtained in step b) by the coefficient associated with each gene in the gene sets in Table 1 to obtain a product for each gene, the coefficients and gene sets of the genes being shown in Table 2;
[0301] d) Sum the products obtained in step c) to obtain a discriminant score (S);
[0302] e) For the gene sets of Table 1, compare the discriminant score (S) obtained in step d) with the centroids of the TEAD - active (A) and TEAD - inactive (I) groups shown in Table 2;
[0303] f) Determine whether (S) is closer to (A) than to (I) according to the formula max(S,A) - min(S,A) < max(S,I) - min(S,I); and
[0304] g) If (S) is closer to (A) than to (I), then characterize the cancer as TEAD - active.
[0305] In some embodiments, the present disclosure relates to a method for measuring the TEAD - activity of a cancer in a subject in need thereof, wherein
[0306] The cancer is a tumor selected from the group consisting of: adrenocortical carcinoma (ACC) tumors; bladder urothelial carcinoma (BLCA) tumors; invasive breast cancer (BRCA) tumors; BRCA basal tumors; BRCA non-basal tumors; cervical squamous cell carcinoma and cervical adenocarcinoma (CESC) tumors; bile duct carcinoma (CHOL) tumors; colon adenocarcinoma (COAD) tumors; COAD CMS1 tumors; COAD CMS4 tumors; lymphoid tumors diffuse large B-cell lymphoma (DLBC) tumors; esophageal carcinoma (ESCA) tumors; glioblastoma multiforme (GBM) tumors; head and neck squamous cell carcinoma (HNSC) tumors; kidney chromophobe cell carcinoma (KICH) tumors; kidney clear cell carcinoma (KIRC) tumors; kidney papillary cell carcinoma (KIRP) tumors; brain low grade glioma (LGG) tumors; hepatocellular carcinoma (LIHC) tumors; LIHC S1 tumors; LIHC S2 tumors; LIHC S3 tumors; lung adenocarcinoma (LUAD) tumors; lung squamous cell carcinoma (LUSC) tumors; LUSC basal tumors; LUSC classical tumors; LUSC primary tumors; LUSC secretory tumors; malignant mesothelioma (MESO) tumors; pancreatic adenocarcinoma (PAAD) tumors; rectal adenocarcinoma (READ) tumors; READ CMS1 tumors; READ CMS2 tumors; READ CMS4 tumors; sarcoma (SARC) tumors; cutaneous melanoma (SKCM) tumors; SKCM immune tumors; SKCM keratin tumors; STAD MSI tumors; STAD MSS_EMT tumors; testicular germ cell tumor (TGCT) tumors; endometrial carcinoma (UCEC) tumors; uterine carcinosarcoma (UCS) tumors,
[0307] and
[0308] The method uses a biological sample of a tumor of the cancer, and
[0309] The method comprises at least the following steps:
[0310] a) measuring the expression level of each gene in a gene set associated with the tumor in the biological sample, wherein the gene set is selected from the group consisting of set a), set c), set d), set e), set g), set i), set j), set l), set m), set q), set r), set t), set v), set x), set y), set aa), set bb), set dd), set ff), set gg), set ii), set kk), set mm), set rr), set ss), set uu), set vv), set xx), set zz), set kkk), set lll), set mmm), set nnn), set ppp), set rrr), set sss), set ttt), set uuu), set zzz), set bbbb), set hhhh), set kkkk) and set llll);
[0311] b) for each gene in the gene set, converting the expression level of the gene into a fractional rank by dividing the rank of the gene by the gene weight of the gene in the gene set;
[0312] c) multiplying each score rank obtained in step b) by a coefficient associated with each gene of the gene set to obtain a product for each gene (P gene i ), the coefficients and gene sets of the genes are shown in Table 2;
[0313] d) determining a discriminant score (DS) of the gene set, wherein the discriminant score (DS) is the product P gene set obtained in step c). i The sum plus the constant coefficient for the gene set shown in Table 2;
[0314] e) for the gene set, comparing the discriminant score (DS) obtained in step d) with a threshold associated with the gene set to determine whether the cancer is TEAD-active or TEAD-inactive, the threshold being shown in Table 3.
[0315] The methods of the present disclosure can be used to characterize a subject as having a TEAD-active cancer or a TEAD-inactive cancer.
[0316] In some embodiments, the cancer may include a solid tumor. In some embodiments, the solid tumor is in the lung, colon, ovary, cervix, uterus, peritoneum, testis, penis, tongue, lymph node, pancreas, bone, breast, prostate, soft tissue, connective tissue, kidney, liver, brain, thyroid or skin. In some embodiments, the cancer can be adrenocortical carcinoma, bladder urothelial carcinoma, invasive breast cancer, cervical squamous cell carcinoma and cervical adenocarcinoma, bile duct carcinoma, consensus molecular type 1 of colorectal cancer, consensus molecular type 2 of colorectal cancer, consensus molecular type 3 of colorectal cancer, consensus molecular type 4 of colorectal cancer, colon adenocarcinoma, lymphoid neoplasms diffuse large B-cell lymphoma, esophageal cancer, glioblastoma multiforme, head and neck squamous cell carcinoma, renal clear cell carcinoma, renal papillary cell carcinoma, brain low-grade glioma, hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, mesothelioma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma and paraganglioma, prostate adenocarcinoma, rectal adenocarcinoma, sarcoma, skin melanoma, gastric adenocarcinoma, testicular germ cell tumor, thyroid cancer, thymoma, endometrial carcinoma or uterine carcinosarcoma.
[0317] In some embodiments, the cancer is a blood cancer. In some embodiments, the blood cancer is leukemia, lymphoma, and myeloma.
[0318] The cancer may be selected from the group consisting of: adrenocortical carcinoma (ACC) tumors; bladder urothelial carcinoma (BLCA) tumors; invasive breast cancer (BRCA); BRCA basal tumors; BRCA non-basal tumors; cervical squamous cell carcinoma or cervical adenocarcinoma (CESC) tumors; bile duct carcinoma (CHOL) tumors; colon adenocarcinoma (COAD) tumors; COAD CMS1 tumors; COAD CMS2 tumors; COAD CMS4 tumors; lymphoid neoplasms diffuse large B-cell lymphoma (DLBC) tumors; esophageal carcinoma (ESCA) tumors; glioblastoma multiforme (GBM) tumors; head or neck squamous cell carcinoma (HNSC) tumors; kidney chromophobe cell carcinoma (KICH) tumors; kidney clear cell carcinoma (KIRC) tumors; kidney papillary cell carcinoma (KIRP) tumors; brain low grade glioma (LGG) tumors; hepatocellular carcinoma (LIHC) tumors; LIHC S1 tumors; LIHC S2 tumors; LIHC S3 tumors; lung adenocarcinoma (LUAD) tumors; LUAD proximal inflammatory tumors; LUAD proximal proliferative tumors; lung squamous cell carcinoma (LUSC) tumors; LUSC basal tumors; LUSC classical tumors; LUSC primary tumors; LUSC secretory tumors; malignant mesothelioma (MESO) tumors; ovarian serous cystadenocarcinoma (OV) tumors; OV differentiated tumors; OV immunoreactive tumors; OV mesenchymal tumors; OV proliferative tumors; pancreatic adenocarcinoma (PAAD) tumors; rectal adenocarcinoma (READ) tumors; READ CMS1 tumors; READ CMS2 tumors; READ CMS4 tumors; READ unclassifiable tumors; sarcoma (SARC) tumors; cutaneous melanoma (SKCM) tumors; SKCM immune tumors; SKCM keratin tumors; SKCM MITF-low expressing tumors; gastric adenocarcinoma (STAD) tumors; STAD MSI tumors; STAD MSS_EMT tumors; STAD MSS_TP53 tumors; STADMSS_TP53+ tumors; testicular germ cell tumor (TGCT) tumors; thyroid carcinoma (THYM) tumors; endometrial carcinoma (UCEC) tumors; and uterine carcinosarcoma (UCS) tumors.
[0319] In some embodiments, the cancer is:
[0320] - adrenocortical carcinoma (ACC) tumor, the gene set of the transcriptional signature is gene set a) or b);
[0321] - bladder urothelial carcinoma (BLCA) tumor, the gene set of the transcriptional signature is gene set c);
[0322] - invasive breast cancer (BRCA) tumors, the gene set of the transcriptional signature is gene set d);
[0323] -BRCA basal tumor, the gene set of the transcriptional signature is gene set e) or f);
[0324] -BRCA non-basal tumor, the gene set of the transcriptional signature is gene set g) or h);
[0325] - cervical squamous cell carcinoma or cervical adenocarcinoma (CESC) tumor, the gene set of the transcriptional signature is gene set i);
[0326] - Cholangiocarcinoma (CHOL) tumor, the gene set of the transcriptional signature is gene set j) or k);
[0327] - colon adenocarcinoma (COAD) tumor, the gene set of the transcriptional signature is gene set 1);
[0328] -COAD CMS1 tumor, the gene set of the transcriptional signature is gene set m) or n);
[0329] -COAD CMS2 tumor, the gene set of the transcriptional signature is gene set o) or p);
[0330] -COAD CMS4 tumor, the gene set of the transcriptional signature is gene set q) or q1);
[0331] - lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) tumor, the gene set of the transcriptional signature is gene set r) or s);
[0332] - esophageal cancer (ESCA) tumor, the gene set of the transcriptional signature is gene set t) or u);
[0333] - a glioblastoma multiforme (GBM) tumor, the gene set of the transcriptional signature is gene set v) or w);
[0334] - head or neck squamous cell carcinoma (HNSC) tumor, then the gene set of the transcriptional signature is gene set x);
[0335] - renal chromophobe cell carcinoma (KICH) tumor, the gene set of the transcriptional signature is gene set y) or z);
[0336] - renal clear cell carcinoma (KIRC) tumor, the gene set of the transcriptional signature is gene set aa);
[0337] - renal papillary cell carcinoma (KIRP) tumor, the gene set of the transcriptional signature is gene set bb) or cc);
[0338] - brain low-grade glioma (LGG) tumor, the gene set of the transcriptional signature is gene set dd) or ee);
[0339] - hepatocellular carcinoma (LIHC) tumor, the gene set of the transcriptional signature is the gene set ff);
[0340] -LIHC S1 tumor, the gene set of the transcriptional signature is gene set gg) or hh);
[0341] -LIHC S2 tumor, the gene set of the transcriptional signature is gene set ii) or jj);
[0342] -LIHC S3 tumor, the gene set of the transcriptional signature is gene set kk) or ll);
[0343] - lung adenocarcinoma (LUAD) tumor, then the gene set of the transcriptional signature is gene set mm);
[0344] -LUAD proximal inflammatory tumor, the gene set of the transcriptional signature is gene set nn) or oo);
[0345] -LUAD proximal proliferative tumor, the gene set of the transcriptional signature is gene set pp) or qq);
[0346] - lung squamous cell carcinoma (LUSC) tumor, the gene set of the transcriptional signature is gene set rr);
[0347] -LUSC basal tumor, the gene set of the transcriptional signature is gene set ss) or tt);
[0348] -LUSC classic tumor, the gene set of the transcriptional signature is gene set uu);
[0349] -LUSC primary tumor, the gene set of the transcriptional signature is gene set vv) or ww);
[0350] -LUSC secretory tumor, the gene set of the transcriptional signature is gene set xx) or yy);
[0351] - malignant mesothelioma (MESO) tumor, the gene set of the transcriptional signature is gene set zz) or aaa);
[0352] - ovarian serous cystadenocarcinoma (OV) tumor, the gene set of the transcriptional signature is gene set bbb);
[0353] -OV differentiated tumor, the gene set of the transcriptional signature is the gene set ccc) or ddd);
[0354] -OV immunoreactive tumor, the gene set of the transcriptional signature is gene set eee) or fff);
[0355] -OV mesenchymal tumor, the gene set of the transcriptional signature is gene set ggg) or hhh);
[0356] -OV proliferative tumor, the gene set of the transcriptional signature is gene set iii) or jjj);
[0357] - pancreatic adenocarcinoma (PAAD) tumor, the gene set of the transcriptional signature is gene set kkk) or kkk1);
[0358] - rectal adenocarcinoma (READ) tumor, the gene set of the transcriptional signature is gene set ll1);
[0359] -READ CMS1 tumor, then the gene set of the transcriptional signature is the gene set mmm);
[0360] -READ CMS2 tumor, the gene set of the transcriptional signature is gene set nnn) or ooo);
[0361] -READ CMS4 tumor, the gene set of the transcriptional signature is the gene set ppp) or ppp1);
[0362] -READ unclassifiable tumor, the gene set of the transcriptional signature is gene set qqq) or qqq1);
[0363] - sarcoma (SARC) tumor, the gene set of the transcriptional signature is gene set rrr);
[0364] - skin melanoma (SKCM) tumor, the gene set of the transcriptional signature is gene set sss);
[0365] -SKCM immune tumor, then the gene set of the transcriptional signature is gene set ttt);
[0366] -SKCM keratin tumor, the gene set of the transcriptional signature is gene set uuu) or vvv);
[0367] -SKCM MITF low-expressing tumor, the gene set of the transcriptional signature is the gene set www) or xxx);
[0368] - gastric adenocarcinoma (STAD) tumor, then the gene set of the transcriptional signature is gene set yyy);
[0369] -STAD MSI tumor, the gene set of the transcriptional signature is gene set zzz) or aaaa);
[0370] -STAD MSS_EMT tumor, the gene set of the transcriptional signature is gene set bbbb) or cccc);
[0371] -STAD MSS_TP53-tumor, the gene set of the transcriptional signature is gene set dddd) or eeee);
[0372] -STAD MSS_TP53+ tumor, the gene set of the transcriptional signature is the gene set ffff) or gggg);
[0373] - testicular germ cell tumor (TGCT) tumor, the gene set of the transcriptional signature is gene set hhhh) or iiii);
[0374] - thyroid cancer (THYM) tumor, then the gene set of the transcriptional signature is gene set jjjj);
[0375] - endometrial carcinoma (UCEC) tumor, the gene set of the transcriptional signature is gene set kkkk); and
[0376] - uterine carcinosarcoma (UCS) tumor, the gene set of the transcriptional signature is gene set llll) or mmmm).
[0377] In some embodiments, the use of a "short TEAD signature" excludes the use of gene sets q1), kkk1), ppp1), and qqq1).
[0378] In some embodiments, the cancer is selected from:
[0379] Adrenocortical carcinoma (ACC) tumors; Bladder urothelial carcinoma (BLCA) tumors; Invasive breast cancer (BRCA) tumors; BRCA basal tumors; BRCA non-basal tumors; Cervical squamous cell carcinoma and cervical adenocarcinoma (CESC) tumors; Cholangiocarcinoma (CHOL) tumors; Colon adenocarcinoma (COAD) tumors; COAD CMS1 tumors; COAD CMS4 tumors; Lymphoid neoplasms Diffuse large B-cell lymphoma (DLBC) tumors; Esophageal carcinoma (ESCA) tumors; Glioblastoma multiforme (GBM) tumors; Head and neck squamous cell carcinoma (HNSC) tumors; Kidney chromophobe cell carcinoma (KICH) tumors; Kidney clear cell carcinoma (KIRC) tumors; Kidney papillary cell carcinoma (KIRP) tumors; Brain low-grade glioma (LGG) tumors; Hepatocellular carcinoma (LIHC) tumors; LIHC S1 tumors; LIHC S2 tumors; LIHC S3 tumors; lung adenocarcinoma (LUAD) tumors; lung squamous cell carcinoma (LUSC) tumors; LUSC basal tumors; LUSC classical tumors; LUSC primary tumors; LUSC secretory tumors; malignant mesothelioma (MESO) tumors; pancreatic adenocarcinoma (PAAD) tumors; rectal adenocarcinoma (READ) tumors; READ CMS1 tumors; READ CMS2 tumors; READ CMS4 tumors; sarcoma (SARC) tumors; cutaneous melanoma (SKCM) tumors; SKCM immune tumors; SKCM keratin tumors; STAD MSI tumors; STAD MSS_EMT tumors; testicular germ cell tumor (TGCT) tumors; endometrial carcinoma (UCEC) tumors; uterine carcinosarcoma (UCS) tumors,
[0380] And the gene set of the transcriptional signature associated with the tumor is set a), set c), set d), set e), set g), set i), set j), set l), set m), set q), set r), set t), set v), set x), set y), set aa), set bb), set dd), set ff), set gg), set ii), set kk), set mm), set rr), set ss), set uu), set vv), set xx), set zz), set kkk), set lll), set mmm), set nnn), set ppp), set rrr), set sss), set ttt), set uuu), set zzz), set bbbb), set hhhh), set kkkk) or set llll). Assay / RNA Sequencing
[0381] In some embodiments, the expression level of a gene can be a nucleic acid expression level, such as an RNA expression level, an mRNA expression level, or a DNA expression level. Any suitable method for measuring nucleic acid expression levels can be used. In some embodiments, RNA-seq is used to measure nucleic acid expression levels. For example, RNA ACCESS protocol or TRUSEQ RIBO-ZERO00 protocol (ILLUMINA), RT-qPCR, qPCR, multiple qPCR or RT-qPCR, microarray analysis, SAGE, Mass-ARRAY technology, or a combination thereof can be used to measure nucleic acid expression levels.
[0382] Methods for evaluating mRNA in cells are well known, and include, for example, RNA sequencing (RNA-seq), whole genome sequencing (WGS), serial analysis of gene expression (SAGE), and various nucleic acid amplification assays (such as RT-PCR), using complementary primers specific to a predetermined gene set. In some embodiments, qRT-PCR is used. In addition, this method may include one or more steps that allow people to determine the level of target mRNA in a biological sample (e.g., by simultaneously checking the level of a comparison control mRNA sequence of a "housekeeping" gene such as an actin family member). In some embodiments, the sequence of the amplified target cDNA may be determined. Optional methods include protocols for checking or detecting mRNA (such as target mRNA) in a tissue or cell sample by microarray technology. Using a nucleic acid microarray, the test and control mRNA samples from the test and control tissue samples are reverse transcribed and labeled to generate cDNA probes. These probes are then hybridized with a nucleic acid array fixed on a solid support. The array is configured so that the sequence and position of each member of the array are known. For example, any TEAD-500 gene or subset of the embodiments described herein can be arranged on a solid support. Hybridization of a labeled probe to a particular array member indicates that the sample from which the probe was acquired expresses that gene. Biological samples
[0383] In some embodiments, the biological sample is a sample of blood, plasma, serum, cerebrospinal fluid (CSF), nasal aspirate, throat swab, vaginal or cervical swab, sputum, tissue, cells, or tumor biopsy.
[0384] In some embodiments, any biological sample comprising one or more tumor cells can be used in the methods disclosed herein. In some embodiments, the sample is selected from a tumor biopsy. In some embodiments, the sample obtained from the subject is a formalin-fixed tumor biopsy. In some embodiments, the sample obtained from the subject is a formalin-fixed paraffin-embedded tumor (FFPE) biopsy or a paraffin-embedded tumor biopsy. In some embodiments, the sample obtained from the subject is a freshly frozen (FF) tumor biopsy. In some embodiments, the sample is a fresh tumor biopsy. In some embodiments, the sample is an archived tumor biopsy. In some embodiments, the sample is a frozen tumor biopsy.
[0385] In some cases of any method and use, the sample is obtained from the individual before the TEAD pathway inhibitor is administered. In some embodiments, the sample is obtained a few minutes, hours, days, weeks, months or years before the TEAD pathway inhibitor as described herein is administered. In other words, the sample can be a baseline sample. In some embodiments, the sample is obtained from the individual after the TEAD pathway inhibitor as described herein is administered. In some cases, a sample from an individual is obtained within thirty hours after endocrine therapy is administered. In some embodiments, the sample is obtained a few minutes, hours or days after the TEAD pathway inhibitor as described herein is administered. In some embodiments, multiple samples are obtained from the same individual at different time points, for example, before and after the TEAD pathway inhibitor as described herein is administered. TEAD pathway inhibitors
[0386] In some embodiments, using the methods and groups described herein, a TEAD pathway inhibitor is administered to a subject identified as having a TEAD-active cancer or who is likely to respond to a TEAD pathway inhibitor. Any TEAD pathway inhibitor known in the art can be administered. For example, the transcription enhancement associated domain (TEAD) protein is a transcription factor composed of four family members (TEAD1-4) that play a role in regulating gene expression in response to the HIPPO pathway. TEAD proteins preferentially associate with transcription coactivators yes associated protein 1 (YAP1) or transcription coactivators (WWTR1, also known as TAZ) with PDZ binding motifs. YAP1-TEAD or WWTR1-TEAD binds to DNA and triggers transcription of a variety of different genes involved in cell proliferation, survival, motility, stemness, and differentiation (reviewed in Holden and Cunningham, Cancer 2018). YAP1 / WWTR1-TEAD activity is strictly controlled by the HIPPO pathway.
[0387] The HIPPO pathway was originally discovered in Drosophila melanogaster as a key regulator of tissue growth. It is an evolutionarily conserved signal transduction pathway that regulates a variety of biological processes, including cell growth and fate determination, organ size control and regeneration. The core of the Hippo pathway in mammals consists of a series of kinases, including MST1 / 2 and LATS1 / 2, their related adapter proteins SAV1 and MOB1, and upstream regulators (such as NF2, SCRIBBLE, CRUMBS and various G protein-coupled receptors). The Hippo pathway is strictly regulated by both internal and external signals (such as mechanical force, cell-to-cell contact, polarity, energy state, stress, and many diffusible hormone factors) (reviewed in Ma S et al. Annu Rev Biochem. 2019; 20; 88: 577-604. Doi: 10.1146 / annurev-biochem-013118-111829). After activation of the Hippo pathway kinase (i.e., the Hippo "on" state), the cytoplasmic YAP1 and WWTR1 proteins are phosphorylated and therefore remain inactive by sequestration in the cytoplasm and / or degradation by the proteasome mechanism. After inactivation of the Hippo pathway kinase (i.e., the Hippo "off" state), the cytoplasmic YAP1 and WWTR1 are no longer phosphorylated and are therefore free to translocate into the nucleus, where they associate with TEAD transcription factors to bind DNA and regulate gene expression. The reduction in pYAP1 / YAP1 levels and the increase in gene expression regulated by YAP1 / WWTR1-TEAD activity and the increase in promoter activity at TEAD-regulated genes are common indicators of YAP1 activation (reviewed in Totaro A et al. Nat Cell Biol. 2018; 20(8): 888-899. Doi: 10.1038 / s41556-018-0142-z).
[0388] The Hippo-YAP1 / WWTR1 / TEAD pathway and human cancer: In recent years, studies have shown that dysregulation of Hippo-YAP1 / WWTR1-TEAD activity is the root cause of tumor progression and resistance to therapy in a variety of different cancer indications and contexts. In mice, systems genetic studies have clearly shown that knockout of HIPPO pathway components (which are YAP1 inhibitors) or overexpression of YAP1 activators (such as YAP1, WWTR1, TEAD) leads to YAP1 activation and YAP1-TEAD-dependent tumor activation and tumor progression (Zhang N et al. Dev Cell. 2010 Jul 2;19(1:27-38. Doi:10.1016 / j.devcel.2010.06.01; Lu L et al. Proc Natl Acad Sci US A. 2010;107(4):1437-42. Doi:10.1073 / pnas.0911427107; Nishio M et al. Proc Natl Acad Sci US A. 2016;113(1):E71-80. Doi:10.1073 / pnas.151718811; Liu-Chittenden Y et al. Genes Dev. 201 2; 26(12): 1300-5. Do i: 10.1101 / gad.192856.112). In humans, genetic alterations in the pathway are most prevalent for NF2 (neurofibromin), an upstream regulator of the core Hippo pathway, which is associated with heritable cancer syndromes and is classified as a tumor suppressor gene. Hundreds of somatically acquired mutations have been reported in NF2 (mostly in meningiomas, mesotheliomas, and peripheral nerve sheath tumors, but also in other cancer types) (reviewed in Schroeder et al. RD et al. Oncotarget. 2014; 5(1): 67-77. Doi: 10.18632 / oncotarget.1557). Genetic alterations outside of NF2 and directly within the core Hippo pathway are less frequently observed in patients and are found to occur at higher rates only in certain indications, such as, for example, malignant mesothelioma. Malignant mesothelioma is a highly lethal serosal cancer and is almost exclusively associated with asbestos exposure. It is a therapeutic indication that shows common alterations in the HIPPO signaling pathway as well as high YAP1 activation and a high dependence on YAP1-TEAD activity (reviewed in Sekido Y. Cancers (Basel). 2018 Mar 22; 10(4): 90. Doi: 10.3390 / cancers10040090).
[0389] Increased YAP1 or YAP1-TEAD activity is not limited to genetic alterations in the HIPPO pathway and can also be the result of upregulation through multiple interconnected signaling pathways. Many pathways that play a key role in tumorigenesis enter the HIPPO-YAP1 / WWTR1 / TEAD1 cascade, and well-described examples include the RTK-RAS-RAF-MEK-ERK, WNT, TGF-β, and AMPK pathways (reviewed in Han YJ Transl Med. 2019; 17(1): 116. Doi: 10.1186 / s12967-019-1869-4). Thus, the number of tumor types that are at least partially dependent on YAP1-TEAD activation is enormous and ranges from breast, ovarian, uterine and prostate cancers to lung, gastric, colorectal, bladder, pancreatic and liver cancers, and further to sarcomas, esophageal cancer, head and neck cancer, uveal melanoma and gliomas (reviewed in Zanconato F et al. Cancer Cell. 2016; 29(6):783-803. Doi: 10.1016 / j.ccell.2016.05.005). Recent studies have revealed the interaction between the HIPPO-YAP / WWTR1 / TEAD pathway and the human immune response (reviewed in Yamauchi T, Moroishi T. Cells. 2019; 8(5):398. Doi: 10.3390 / cells8050398).
[0390] YAP1 activation has been observed in the context of resistance to therapy and is considered to be a major mechanism for resistance and survival to anticancer therapy. In esophageal cancer, YAP1 is a positive regulator of EGFR (epidermal growth factor receptor) and the induction of YAP1 is associated with resistance to 5-FU and docetaxel. In the context of targeted therapy, YAP1 in BRAF mutant tumors acts as a parallel survival input to promote resistance to RAF and MEK inhibitor therapy in melanoma. Similarly, YAP1 activation is a mechanism for survival of EGFR and MEK inhibitor therapy in the context of EGFR mutant lung cancer, and multiple studies have identified YAP1 activation as one of the main bypass mechanisms of KRAS inhibition. In the context of hormone-dependent tumors, WWTR1 inhibition has been shown to restore sensitivity to tamoxifen in breast cancer. In prostate cancer cells, androgen deprivation therapy resistance is associated with increased YAP1 nuclear localization and activity (reviewed in Reggiani F et al. Biochim Biophys Acta Rev Cancer. 2020; 1873(1):188341. Doi:10.1016 / j.bbcan.2020.188341; Kurppa KJ et al. Cancer Cell. 2020; 37(1):104-122.e12. doi:10.1016 / j.ccell.2019.12.006).
[0391] Therefore, the HIPPO-YAP / WWTR1 / TEAD pathway is a key player in cancer development and tumor maintenance, and targeting this pathway is key to cancer treatment in the first-line therapy setting as well as in the context of overcoming drug resistance in multiple cancer indications.
[0392] As used herein, a "TEAD pathway inhibitor" can be a small molecule or macromolecular compound that inhibits the HIPPO-YAP / WWTR1 / TEAD pathway. Additional anticancer therapies
[0393] In some embodiments, the methods disclosed herein further include administering a TEAD pathway inhibitor and an additional anticancer therapy. The additional anticancer therapy may include any therapy and / or any standard of care therapy known in the art for treating a tumor in a subject. In some embodiments, the additional anticancer therapy includes surgery, radiotherapy, chemotherapy, immunotherapy, hormone therapy, or any combination thereof. In some embodiments, the additional anticancer therapy includes chemotherapy. In some embodiments, the additional anticancer therapy includes immunotherapy. In some embodiments, the additional anticancer therapy includes hormone therapy. Kits and Products
[0394] In some embodiments, provided herein is a kit or article of manufacture containing any one of the panels described herein or materials useful for preparing such panels.
[0395] In some embodiments, the kit or article of manufacture can include one or more reagents for preparing a sample for RNA sequencing analysis.
[0396] In some embodiments, the kit or article of manufacture further comprises one or more reagents for determining a TEAD inactivity or TEAD activity score from a sample.
[0397] In some embodiments, the kit or article of manufacture may comprise instructions for using the kit for any of the methods / uses as described herein.
[0398] In some embodiments, the kit or article of manufacture may comprise a container, a label on the container, and a composition contained within the container, wherein the composition comprises one or more polynucleotides that hybridize under stringent conditions to the complement of a gene listed herein, and the label on the container indicates that the composition can be used to assess the activity of a set of genes listed herein, and wherein the kit comprises instructions for using the one or more polynucleotides to assess the presence of RNA or DNA of the genes in a particular sample type.
[0399] In some embodiments, the test kit or article is based on oligonucleotides and may include, for example, (1) oligonucleotides, such as detectably labeled oligonucleotides, which hybridize to a nucleic acid sequence encoding a protein, or (2) primers that can be used to amplify nucleic acid molecules. In some embodiments, the test kit or article may also include a buffer, a preservative, or a protein stabilizer. In some embodiments, the test kit or article may further include components necessary for detecting a detectable label, such as an enzyme or a substrate. In some embodiments, the test kit or article may also contain a control sample or a series of control samples, which may be measured and compared with a test sample. In some embodiments, each component of the test kit or article may be packaged in a separate container, and all different containers may be placed in a single package together with instructions for explaining the results of the determination performed using the test kit or article. Example 1 Materials and methods
[0400] Key details of the materials and methods used are provided below. Compilation of the TEAD-500 gene list.
[0401] We reviewed the published data sets and selected genes that were differentially expressed at p-values < 0.01 by comparing treated samples with their corresponding controls for analysis of variance. The resulting 37 gene lists were compiled into one. Genes that were observed to be regulated only once, as well as genes that were inconsistently regulated between experiments, were removed from the compilation. The remaining approximately 700 genes that were consistently regulated in at least 2 experiments were ranked by increasing p-values, and the top 500 effectors were finally selected for routine querying in large cohorts. Calculation of TEAD-500 tag scores.
[0402] TEAD-dependent transcription was scored in individual samples as the difference Rp-Rn, where Rp is the mean score rank of positive effectors and Rn is the mean score rank of negative effectors.
[0403] We consider the most abundant transcripts of genes to be representative of the gene expression. Therefore, we retain the expression level of the main transcript (the maximum level value for each gene and sample, which can be expression array signals, RNA sequencing counts, fragments per kilobase per million counts (fragments per kilobase per million counts, FPKM), transcripts per million reads (transcripts per million, TPM) or any other convenient measurement index) and discard the values of all other transcripts. By dividing by the maximum expression value of all genes (the most abundant genes) observed in the sample, the maximum expression level of the gene is converted into a score rank. No other normalization is required.
[0404] Due to technological developments (from various commercial expression arrays to RNA sequencing technologies), and also due to inconsistencies in gene nomenclature, in reality the set usually does not contain the 500 genes reported in the training data set from TEAD-500. However, deletions up to at least 10% only negligibly affect its score. This is one of the reasons why TEAD-500 is highly robust. Epidemiological and experimental testing datasets.
[0405] We scored TEAD-dependent transcription in approximately 9,000 normal tissue samples from the Genotype-Tissue Expression Project (GTEx Portal as of 09 / 24 / 21; https: / / gtexportal.org / home / ) in primary, recurrent, or metastatic tumors of The Cancer Genome Atlas (TCGA; approximately 11,000 samples; https: / / www.cancer.gov / tcga) and divided them into “TEAD-active” and “TEAD-inactive” categories, and scored laboratory cell lines in the Cancer Cell Line Encyclopedia (CCLE; approximately 1,000 samples; https: / / sites.broadinstitute.org / ccle / ) to select experimental models. We further applied the labeling to track the extent of TEAD inhibition in cells and tumor models following YAP1 or TEAD1 knockdown or by pharmacological inhibition using the recently published (Kaneda A et al. Am J Cancer Res. 2020; 10(12):4399-4415) TEAD palmitoylation inhibitor K-975 (Kyowa Kirin Co., Ltd., Shizuoka, Japan). Cells and culture conditions.
[0406] All cell lines were grown at 37° C. under 5% CO 2 . MSTO-211H (no. CRL-2081), NCI-H226 (no. CRL-5826), NCI-H2052 (no. CRL-5915), NCI-H28 (no. CRL-5820) and HCT116 (no. CCL-247) were purchased from the American Type Culture Collection (ATCC, Manassas, Virginia, USA) and cultured according to the supplier's recommendations. ZL5 (no. 11120715), ZL34 (no. 11120713), SPC212 (no. 11120717), Mero-14 (no. 09100101), Mero-48a (no. 09100104), Mero-95 (no. 09100108), JU77 (no. 10092309), LO68 (no. 10092311) and ONE58 (no. 10092313) were purchased from the European Collection of Authenticated Cell Cultures (ECACC, Public Health England, Salisbury, UK) and cultured according to the supplier's recommendations. All cell lines were authenticated by short tandem repeat assay at Microsynth AG (Bargach, Switzerland). VenorTM Mycoplasma infection was excluded by PCR using the GeM Mycoplasma Detection Kit (Biovalley, Nanterre, France). Cell line transfections and constructs.
[0407] By using TM We generated cell lines stably expressing sh-YAP1, sh-Null, or TEAD2-DN by transducing MSTO-211H and HCT116 cells with the PiggyBac transposon vector using the Lipofectamine 3000 reagent protocol from Pharmacopoeia (Wilmington, DE). Transduced cells were selected in medium supplemented with 1 mg / ml puromycin. To generate the PiggyBac constructs, the DNA sequences of sh-YAP1 and sh-Null were cloned into the pPiggyBac-KO-Tet-One-PuroDEST plasmid. The DNA sequence of human TEAD2-DN (Ser112-Asp447; Liu-Chittenden, Y. et al., Genes Dev, 2012. 26(12):1300-5) with a FLAG tag at the N-terminus was cloned into the pPiggyBac-A-Tet-One-puroDEST vector. Cell growth and apoptosis assays.
[0408] Cells were seeded in medium supplemented with or without doxycycline (1 μg / ml) and incubated for 96 hours at 37°C and 5% CO2. Cell growth was measured by trypan blue dye exclusion using a Vi-CELL-XR cell viability analyzer (Beckman Coulter). Caspase-3 / 7 activity was detected using Cell-Event Caspase-3 / 7 Green Ready-Probes reagent (Molecular Probes), and caspase-3 / 7 activity was detected by IncuCyte TM The activity was measured by ZOOM live cell analysis system (Essen Bioscience), scanning every two hours for 72 hours. The fluorescence signal of activated caspase 3 / 7 obtained was normalized (= normalized apoptosis), with good confluence at each time point. During the assay, peak apoptosis was determined as the highest normalized caspase 3 / 7 activity value. animal.
[0409] Female CB17 / lcr-Prkdc scid / lcrIcoCrl mice (6–8 weeks old) were bred at Charles River (Les Oncins, France), housed in a Sanofi AAALAC-accredited animal facility, and provided irradiated food and filtered water ad libitum. In vivo xenograft studies.
[0410] In 3×10 6 cells and 10×10 6 Thirteen malignant mesothelioma cell lines (MSTO-211H; ZL5; NCI-H226; JU77; MERO 48A; MERO 95; H2052; ZL-34; SCP-212; MERO-14; Lo68; One58; H28) were evaluated for in vivo tumor growth by subcutaneously inoculating cells into the right flank of SCID mice. 6 In vivo target validation studies were performed on MSTO-211H-TEAD2-DN, MSTO-211H-shYAP1, and HCT116-shYAP1 cell lines inoculated subcutaneously with 100 cells. Mice were divided into two groups immediately after cell implantation. Each group received drinking water supplemented with either doxycycline and 5% glucose or 5% glucose alone.
[0411] In use 3×10 6 MSTO-211H or NCI-H226 cells were subcutaneously inoculated into SCID mice on the right flank for in vivo efficacy studies of K-975 compounds. Mice carrying approximately 200 mm3 subcutaneous MSTO-211H tumors or 150 mm3 subcutaneous NCI-H226 tumors were randomly assigned to 5 groups of 8 mice each, and they were treated twice daily with vehicle or K-975 compounds at 30, 100 and 200 mg / kg for 18 consecutive days. The vertical diameter of the tumor was measured twice a week with a caliper, and the tumor volume (V) was calculated according to the following formula: V (mm3) = (d2 (mm2) x D (mm)) / 2, where d is the minimum vertical tumor diameter and D is the maximum vertical tumor diameter. In vitro validation.
[0412] First, a genetic approach based on a TEAD dominant negative (TEAD2-DN) construct was used to test the effect of YAP1 downregulation on tumor growth in vitro. This construct was previously reported as an effective inhibitor of YAP1 activity (Liu-Chittenden, Y. et al., Genes Dev, 2012.26(12):1300-5), which is based on a truncated form of TEAD2 that lacks a DNA binding domain but retains its ability to associate with YAP1. Therefore, it acts as a non-functional competitor of endogenous TEAD bound to YAP1.
[0413] We engineered this construct to be flanked by a doxycycline-inducible promoter and used the construct for stable transfection of MSTO-211H cells. Following the addition of doxycycline, TEAD2-DN expression resulted in a 66% inhibition of tumor cell growth in vitro 96 h after doxycycline induction ( Figure 3 A- Figure 3 B), accompanied by a significant decrease in TEAD-500 score and classical TEAD activity protein markers CYR61 and CTGF.
[0414] The latter protein marker was measured by ELISA assay. Cell lysates were diluted 1 / 500 in cell lysis buffer. For each model, a minimum of four biological replicates were analyzed. Standards and samples were run in duplicate in the readout plate. Human Cyr61 Quantikine TM hCYR61 was assessed using a colorimetric sandwich ELISA kit (R&D Systems, Minneapolis, MN). Diluted lysates were processed and analyzed as described in the manufacturer's instructions. Absorbance values were read using a microplate reader set at 450 nm. In vivo validation.
[0415] We generated cell lines stably expressing sh-YAP1, sh-Null or TEAD2-DN by transducing MSTO-211H and HCT116 cells with piggyBac transposon vectors using the Lipofectamine 3000 reagent protocol from Thermo Fisher. Transduced cells were selected in medium supplemented with 1 mg / ml puromycin. To generate piggyBac constructs, DNA sequences of sh-Yap1 and sh-Null were cloned into pPiggyBac-KO-Tet-One-Puro DEST plasmids. DNA sequences of human TEAD2-DN (Ser112-Asp447; Liu-Chittenden, Y. et al., Genes Dev, 2012. 26(12): 1300-5) with a FLAG tag at the N-terminus were cloned into pPiggyBac-A-Tet-One-puro DEST vectors. NCI-MSTO-211H malignant mesothelioma cells were transfected with a doxycycline-dependent dominant-negative TEAD1 shRNA (TEAD DN), implanted subcutaneously into SCID mice, and allowed to grow for 26 days. YAP1 shRNA was induced in established tumors and resulted in tumor regression in all mice tested.
[0416] RNA sequencing.
[0417] Fresh tumors were stored in RNAlater (Thermo Fisher) and frozen at -200°C. Co-purification of miRNA and total RNA was performed using the miRNeasy mini kit (QIAGEN, 217004). RNA concentration and purity were evaluated using an ND-1000 spectrophotometer (NanoDrop, Thermo Fisher). Quality indicators were RNA integrity index (RIN) and DV200 value (% of RNA fragments with a length ≥ 200 nt). 100 ng of total RNA per sample was used as input material for library preparation. Libraries were prepared using the KAPA HyperPrep kit according to the manufacturer's recommendations, and KAPA target enrichment was performed using Illumina's KAPA HyperCap V3.0 kit (all kits were purchased from Kapa Biosystems, Wilmington, Massachusetts). Libraries were sequenced using the NextSeq 500 paired-end sequencing platform (Illumina Inc., San Diego, California). Discriminant function.
[0418] To calculate tissue-specific combinations of predictors of TEAD activity, a classic statistical method called Fisher stepwise linear discriminant function analysis was used. The algorithm builds a linear model in a stepwise manner. The most significant predictor (in this case, the most significant effector gene) enters the model first. The data for this predictor is standardized. At each step, the predictor that minimizes the overall Wilks' lambda is entered into the formula. All predictors in the model are re-evaluated. Those predictors that are no longer significant are deleted from the model. When all predictors in the model are significant and all predictors remaining outside the model are not significant, the selection of predictors stops. These calculations use SPSS statistical software (IBM, Armonk, New York). result Robustness of the TEAD-500 score.
[0419] Due to the large number of genes in the TEAD-500 list and the high redundancy of this signature (correlation between genes), its score is largely unaffected by gene deletion. We simulated deletion by generating two random subsets, each containing only 90% of the genes. A different 10% of the genes were omitted from each subset. Using these different subsets, we calculated the dgR scores for 1112 experimental samples. These samples are cell lines with TEAD-500 scores at the upper limit of the scale (TEAD activated), but grown under various TEAD inhibitory conditions. Figure 2 As shown, the correlation between the scores for the two random damages is almost perfect (R2 = 0.997). In vitro validation of the TEAD-500 score.
[0420] When the malignant mesothelioma cell line NCI-H226 was treated with a benchmark TEAD inhibitor (K-975; see, e.g., Kaneda A et al. Am J Cancer Res. 2020; 10(12):4399-4415) for 24 h, the TEAD-500 score regressed in a dose-dependent manner ( Figure 3 A- Figure 3 B). The same is true for the RNA and protein levels of CYR61, a classic secretory marker of Hippo pathway activity ( Figure 3 C). In vivo validation of the TEAD-500 score.
[0421] NCI-MSTO-211H malignant mesothelioma cells were transfected with a doxycycline-dependent dominant-negative TEAD1 shRNA, implanted subcutaneously into SCID mice, and allowed to grow for 26 days. YAP1 shRNA was induced in established tumors and resulted in tumor regression in all mice tested ( Figure 4 A). Tumor regression was accompanied by a significant decrease in TEAD-dependent transcription (TEAD-500 score) ( Figure 4 B) Thus, TEAD-dependent transcription is essential for tumor maintenance in malignant mesothelioma in vivo. TEAD-500 as a pharmacodynamic marker.
[0422] The same type of events were observed when SCID mice implanted with malignant mesothelioma parental NCI-H226 cells were treated with 200 mg / kg BID of the benchmark TEAD inhibitor K-975 (Kaneda A et al. Am J Cancer Res. 2020; 10(12):4399-4415) for 17 consecutive days ( Figure 5 ). In this model, about 30%-40% inhibition of TEAD-dependent transcription appears to be sufficient for tumor regression. A dose of 100 mg / kg BID is still active with ΔT / ΔC=12 (almost tumor stasis), while a dose of 30 mg / kg BID is inactive. Therefore, the TEAD-500 score correlates with tumor behavior under treatment and can be used as a marker for the pharmacodynamics or efficacy of a drug. Epidemiology of the TEAD-500 score.
[0423] Figure 6We show that the distribution of TEAD-500deR scores is shifted toward higher values in tumors (TCGA) compared to normal tissues (GTEx). Primary tumors tend to have higher scores than adjacent normal tissues. Recurrent and metastatic tumors have higher scores than primary tumors. Thus, at least in some cases, TEAD-dependent transcription increases with tumorigenesis and tumor progression. This result is consistent with multiple observations that the TEAD pathway confers a mechanism for evading therapy (Coggins GE et al. Cancer Res. 2019; 79(24): 6204-6214. Doi: 10.1158 / 0008-5472. CAN-19-1415; Ansari D et al. Anticancer Res. 2019; 39(7): 3317-3321. Doi: 10.21873 / anticanres.13474; Kim CG et al. Cancer Immunol Res. 2018; 6(3): 255-266. Doi: 10.1158 / 2326-6066. CIR-17-0320).
[0424] Among all the TCGA groups tested, primary malignant mesothelioma is an indication with very high TEAD activity. Its average TEAD-500 score is even higher than that of metastatic tumors. This confirms the published observations that TEAD-dependent transcription in malignant mesothelioma (Mizuno, T., Murakami, H., Fujii, M. et al. Oncogene 31, 5117-5122 (2012). https: / / doi.org / 10.1038 / onc.2012.5) and makes a reasonable explanation for the selection of mesothelioma as a gateway indication (https: / / www.bolderscience.com / trial / nct04665206 / ) for the proof-of-concept phase clinical trial of new TEAD inhibitors. Cell lines (CCLE) get higher scores, probably because they are colonies of advanced tumor cells. The mesothelioma cell lines tested are among the cell lines with high scores. We also confirmed the already published observation that TEAD-dependent transcription is increased in cervical cancers with YAP1 amplification ( Figure 7 ; Lorenzetto E et al. Oncotarget. 2014; 5(9):2608-21; doi:10.18632 / oncotarget.1844). Prognostic value of the TEAD-500 score.
[0425] The mesothelioma cohort (TCGA MESO) was divided into two equal groups according to the TEAD-500deR score of the tumor samples. The median overall survival of patients with low scores was 826 days, which is about 2.3 times the median survival of 361 days for patients with high TEAD-500 scores ( Figure 8 ). The differences were significant according to all log-rank (p=0.011), Breslow (p=0.004), and Tarone-Ware (p=0.006) tests. When all TCGA indications were combined and divided into three equal groups according to TEAD-500 scores, we again observed very significant differences in overall survival between the three groups, with p values less than 1E-15 for all three statistical tests. The median survival of the group with the highest score was only 1583 days, while the group with a medium score was 2331 days, and the group with the lowest score was 2823 days ( Fig. 9 ). TEAD-500 is independent of classical markers.
[0426] There were some significant but rather weak (considering the large sample size) correlations between the scores of the best discriminant function (Table 4) or the minimum discriminant function (Table 5) and RNA levels of two markers, CCN1 and CCN2, which are commonly used to measure YAP1 or TEAD activity. Significant correlations were only observed in some cancer indications or subtypes. These correlations can be interpreted as another validation of our approach. However, for most cohorts, the discriminant score appeared to be an independent predictor of TEAD pathway activity, especially in tissues where CCN1 and CCN2 are biologically unrelated. Table 4. Significance of correlation between the best discriminant function scores and RNA levels of the canonical TEAD pathway activation markers CCN1 and CCN2 according to cancer indication and subtype (p values < 0.05 are highlighted in bold) Table 5. Significance of correlation between minimum discriminant function scores and RNA levels of canonical TEAD pathway activation markers CCN1 and CCN2 according to cancer indication and subtype. Performance of the discriminant function as a classifier.
[0427] Several metrics can be calculated to evaluate the performance of a classifier based on the number of positive (P; TEAD-500>0.055) and negative (N; TEAD-500<0.055) samples and true positive (TP), true negative (TN), false positive (FP), and false negative (FN) predictions. The positive prediction result (PP) is the sum of TP+FP. The negative prediction result is the sum of TN+FN. The incidence of positive samples in a population (cohort) is the proportion of positives, P / (P+N). The accuracy of the prediction is the proportion of samples correctly classified, (TP+TN) / (P+N). Precision, also known as the positive predictive value (PPV), is the proportion of true positives among all predicted positives, TP / PP. The false discovery rate (FDR) is the proportion of false positives among predicted positives, FP / PP or 1-PPV. The false omission rate (FOR) is the proportion of predicted negatives that are true negatives, FN / PN or 1-NPV (negative predictive value). The negative predictive value (NPV) is the proportion of predicted negative results that are true negative results, TN / PN or 1-FOR. Sensitivity, also known as the true positive rate (TPR), recall or predictive power, is the proportion of positive results that are so truly predicted, TP / P. Specificity, selectivity or true negative rate (TNR) is the proportion of negative results that are so truly predicted, TN / N. The false negative rate (FNR) or miss rate is the proportion of positive results that are wrongly predicted to be negative results, FN / P.
[0428] The F-score or F-measure is a measure of test accuracy commonly used in statistical analysis of binary classification. This is calculated based on the precision and sensitivity of the test as:
[0429] F score = (2x PPV x TPR) / (PPV + TPR) or 2x TP / (2x TP + FP + FN)
[0430] Perhaps the most commonly used single measure of classifier performance is the informativeness or Youden's J statistic (also called the Youden index), which is defined as TPR + TNR - 1 in terms of sensitivity (true positive rate) and specificity (true negative rate). This is a single statistic that captures the performance of a dichotomous diagnostic test.
[0431] Table 6 shows the values of these metrics for all our discriminative classifiers, whether they are the best or the smallest. Of the 57 published classifiers, 40 achieved perfect discrimination (informativeness = 1) of tumors with TEAD-active pathways compared to tumors with TEAD-inactive pathways, as these are defined by our universal TEAD-500 label. Another 10 classifiers had excellent performance, achieving informativeness values greater than or equal to 0.9. Another 5 classifiers increased the probability of correct patient selection from 18% or less than 10% (incidence or prior probability values) to the range of 85%-90%. Even our most common function applied to the THYM and READ cohorts can provide reliable (informed) correct decisions with a probability (rate) of 59% and 76%, respectively (rather than the 4% and 7% achieved by chance). Table 6: Performance of discriminant functions as classifiers of TEAD pathway status across TCGA indications and tumor subtypes. Example 2 Mesothelioma - Comparison of the best and smallest discriminant function scores with the TEAD-500 score.
[0432] Fig.10 and Fig.11 The relationship between the best and minimum discriminant function scores and the gold standard measure of TEAD pathway activity according to the TEAD-500 score is shown. The TEAD-500 score varies continuously along the horizontal axis, but is divided into TEAD active or TEAD inactive groups according to an arbitrary threshold based on a set of experimental observations (mesothelioma cell lines that respond or do not respond to siRNA knockdown of YAP1). On the vertical axis, the score of the best discriminant function ( Fig.10 ) easily separated the samples into two completely different groups and predicted the response of mesothelioma tumors - assuming that the primary tumors were comparable to our cell lines - but using fewer predictive genes than TEAD-500. The score of the minimum discriminant function for the same indication, based on even fewer predictors, still distinguished the two groups ( Fig.11 ). However, the distance between groups is smaller and the risk of misclassification of new samples is greater, especially when the collected data are incomplete. Fig.12 The scores of the best and minimum discriminant functions are compared in , and the coordinates of the centroid of each group are shown for both functions. Discriminant score and category calculator.
[0433] Table 7 and Table 8 present the simulation of sample discrimination. Two mesothelioma samples are used as examples. According to the TEAD-500 score, sample 1 has a TEAD active pathway, while in sample 2, the pathway is inactive. The best set of predictors is listed in column A, and their coefficients are listed in column B. A subset of prediction pointers is used in the minimum discriminant function. Their coefficients are in column C. Columns D and E show the quantile-normalized expression data of these samples and genes. Among the genes in the TEAD-500 list, the score grades of the RNA levels of the prediction pointers are in columns F and G. Columns H and I contain the product of the score grades of the genes in the two samples (columns F and G) multiplied by the coefficients of the genes in the best function (column B). Similarly, columns J and K contain the product of the score grades of the genes in the two samples (columns F and G) multiplied by the coefficients of the genes in the minimum function (column C).
[0434] Row 29 contains the constants for the best and minimum functions, in cells B29 and C29, respectively. These constants are added to the sum of products in column HK, accordingly. The total score for the sample is shown in row 31. The distance of each score from each centroid is measured as:
[0435] Distance = max(score, centroid) - min(score, centroid)
[0436] In this example, Sample 1 scores closer to the centroid of the active group (2.76, using the best function; or 0.21, using the smallest function) than to the centroid of the inactive group (best distance = 14.96; smallest distance = 5.71). Therefore, it is safely classified as active. Similarly, comparing the score of Sample 2 (best score in I31 and smallest score in K31) with the centroid of the two functions of the two groups, we find that both scores are closer to the centroid of the inactive group (comparing I32 with I33 for the best function or K32 with K33 for the smallest function). Therefore, Sample 2 is classified as inactive. Table 7. Discriminant score calculator. Table 8 Example 3: Determination of the Discriminant Score (DS) of the Optimal Discriminant Function Determination of (DS) score
[0437] The dimensionality of the test is reduced from the TEAD500 set to a subset of the most informative genes applicable to a specific cancer type. These smaller groups (or sets) of genes allow prediction of the state (active or inactive) of the TEAD complex in samples from a given cancer indication or subtype.
[0438] Using the optimal discriminant function determined for gene sets a) to mmmm), a discriminant score (DS) can be calculated to be compared with a predetermined threshold for classifying a cancer or tumor sample as a TEAD-active cancer or a TEAD-inactive cancer.
[0439] The (DS) score for a given cancer indication can be determined as follows:
[0440] 1. In a tumor sample from an individual with cancer, determine the expression level of the genes listed in the best discriminant function of the gene set associated with a specific tumor. The expression level can be determined by RNA sequencing, NGS, RT-qPCR or any other reliable method.
[0441] 2. For each gene tested, the expression level of the gene was converted to a fractional rank, which, according to the definition herein, is the rank of the gene (i.e., the expression of the gene is relative to all genes tested, where the gene with the lowest expression level is assigned a rank of 1, the gene with the second highest expression level is assigned a rank of 2, and so on, until the highest expressed gene is assigned the highest rank; equal expression levels are assigned an average rank, e.g., two genes with zero expression are assigned a rank of 1.5) divided by the number of genes tested.
[0442] 3. Multiply the score rank of each gene by the corresponding coefficient provided by the best discriminant function of the gene set associated with the indication to obtain the product for each gene (P gene i ).
[0443] 4. The discriminant score (DS) of the tested gene set of the tumor sample is calculated as the product of all discriminant genes P gene i plus the constant coefficient of the discriminant function according to the following formula:
[0444] (DS) = ΣP gene i + constant coefficient of the discriminant function for the gene set tested,
[0445] Among them, genes i are the genes listed in the discriminant function of the gene set tested, and P genes i Equal to gene i Score level*Gene i The coefficient of .
[0446] For example, if the best discriminant function for the indication to which the sample belongs has 10 genes, we multiply the score rank of each gene by the corresponding discriminant coefficient (called loading) of the gene, and we add the resulting product to the constant coefficient of the best discriminant function.
[0447] 5. Determine the TEAD activity status of the sample by comparing the (DS) of the tested gene set with the thresholds for each indication listed in Table 3. Table 3. Thresholds used to determine the "TEAD active" or "TEAD inactive" status of tumors for each cohort (indication or sub-indication). NA: Not applicable
[0448] Depending on the indication, (DS) must be below or above a given threshold to identify a cancer as TEAD-active. Performance of Discriminant Score (DS)
[0449] The performance of the discriminant score (DS) was evaluated from the confusion matrix (true positive, true negative, false positive and false negative counts) using the thresholds in Table 6 according to standard epidemiological metrics (https: / / en.wikipedia.org / wiki / Sensitivity_and_specificity) and is presented in Table 9.
[0450] Several metrics can be calculated to evaluate the performance of the classifier based on the number of positive (P) and negative (N) samples (determined by comparing DS to the thresholds in Table 6) as well as true positive (TP), true negative (TN), false positive (FP), and false negative (FN) predictions.
[0451] TP is a subject with TEAD-active cancer who was correctly identified as having TEAD-active cancer; FP is a subject with TEAD-inactive cancer who was incorrectly identified as having TEAD-active cancer; TN is a subject with TEAD-inactive cancer who was correctly identified as having TEAD-inactive cancer; and FN is a subject with TEAD-active cancer who was incorrectly identified as having TEAD-inactive cancer.
[0452] The positive predictive value (PP) is the sum of TP+FP. The negative predictive value (NP) is the sum of TN+FN. The incidence of positive samples in a population (cohort) is the proportion of positives, P / (P+N). The accuracy of the prediction is the proportion of correctly classified samples, (TP+TN) / (P+N). Precision is also called the positive predictive value (PPV), which is the proportion of true positive results among all predicted positive results, TP / PP. The false discovery rate (FDR) is the proportion of false positives among predicted positive results, FP / PP or 1-PPV. The false omission rate (FOR) is the proportion of predicted negative results that are true negative results, FN / PN or 1-NPV (negative predictive value). The negative predictive value (NPV) is the proportion of predicted negative results that are true negative results, TN / PN or 1-FOR. Sensitivity is also called the true positive rate (TPR), recall or predictive power, which is the proportion of positive results that are so truly predicted, TP / P. Specificity, selectivity or true negative rate (TNR) is the proportion of negative results that are so truly predicted, TN / N. The false negative rate (FNR) or miss rate is the proportion of positive results that are incorrectly predicted as negative results, FN / P.
[0453] The “F1 score” in Table 9 is a measure of test accuracy. This is calculated based on the precision and sensitivity of the test as:
[0454] F1 score = (2x PPV x TPR) / (PPV + TPR) or 2x TP / (2x TP + FP + FN)
[0455] "Informativeness" in Table 9 is a measure of the performance of the method for each cancer type, which is defined as TPR+TNR-1 in terms of sensitivity (true positive rate) and specificity (true negative rate).
[0456] The values of these metrics for all discrimination scores (DS) are shown in Table 8. Of the 43 (DS) disclosed, 20 achieved perfect discrimination (information = 1) for tumors with TEAD active pathways. Another 10 (DS) had excellent performance, achieving informative values greater than or equal to 0.9. Another 5 (DS) had correct performance for patients achieving informative values ranging from 85%-90%, and 8 (DS) had moderate performance ranging from 0.6 to less than 0.85, and only one (DS) had a performance slightly below 0.5 (0.46). Table 9: Performance of the discriminant score when only the best associated genes are queried according to method 3B according to cancer type or subtype
[0457] The results indicate that the discriminant score (DS) obtained using the optimal discriminant function defined for genes a) to mmmm) and the associated cancer indication is a useful and effective tool for classifying a patient's cancer as TEAD-active or TEAD-inactive and for managing the patient's treatment.
Claims
1. Use of a transcriptional signature for characterizing TEAD activity of a cancer in a subject in need thereof, the transcriptional signature being obtained by measuring the expression levels of genes of a gene set in a biological sample of a tumor of the cancer, the gene set comprising: Any 220 to 249 genes from the following gene set (1): AASS, ABAT, ACAT2, ADAMTS1, ADM, ADRB2, AMOT, ANXA3, ARHGAP11A, ARHGDIB, AURKB, AVPI1, AXL, AZIN1, B4GALT4, BCAT1, BIRC5, BTG3, C4BPB, CAP2, CAV1, CAVIN1, CCBE1, CCDC80, CCN1, CCN2, CDC25A, CDC6, CDCA3, CDCA4, CDCA5, CDCA8, CDH4, CDK2, CDK6, CDV3, CENPA, CENPI, CEN PM, CENPN, CHRNB1, CHST13, CKS2, CLDN1, CLIC3, CNN3, COBL, COL8A1, COTL1, CPA4, CRIM1, CRY1, CTH, CXCL1, CYTH3, DAPK1, DCLRE1B, DDAH1, DHCR7, DHFR , DIAPH3, DKK1, DLL1, DONSON, DUSP14, DUT, EBP, EIF2AK3, EMG1, EPHA2, EPS8L2, ESM1, ETS1, EXO1, EXOSC2, F3, FAHD2A, FAM83D, FANCA, FAT4, FDPS, FEN1 , FMR1, FST, FSTL1, FSTL3, GADD45A, GADD45B, GINS1, GPC6, GPR176, GPRC5A, GPRC5B, GRAMD2B, HASPIN, HEG1, HEXB, HPS5, HSPB11, IDI1, IGFBP7, IKBIP , IL6, ITGB2, JDP2, JPH2, KPNA2, KRT8, KRT80, LCA5, LHFPL6, LMCD1, LMNB2, LRP8, LRRFIP2, LSM5, LYPD6, LYRM1, MAD2L1, MAP6D1, MATN2, MATN3, MCM10, M CM2, MCM5, MDC1, METRNL, MICB, MID1, MRPL33, MSRB3, MVD, MXRA7, NCAPD3, NEDD4, NEDD4L, NEK2, NEXN, NFIB, NNMT, NOC3L, NTN4, NUAK1, NUAK2, NUDCD1, N UP107, NUP37, OGFRL1, OLFML3, OLR1, OXCT1, PAK2, PCBD1, PCNA, PDLIM2, PDZD2, PEPD, PHLPP1, PKMYT1, PKP2, PKP4, PLCE1, PLEKHA7, PLK2, PLOD2, PPIH,<h2 style=";text-align:left;direction:ltr">PRPS1、PRPS2、PRSS23、PSG2、PSG6、PSG7、PSG9、PVR、PXMP2、QDPR、QKI、RAB11F IP1、RAB32、RACGAP1、RBM24、RBMS2、RCN2、RFC4、RND3、RNF144B、ROR1、RPS24、S CD5、SCML1、SDC2、SEC14L1、SGK1、SGMS2、SGTB、SH3RF1、SHCBP1、SKP2、SLC25A 23、SLC25A3、SLC38A5、SLC3A2、SLC7A1、SLC7A5、SMPD4、SNAPC1、SNX24、SORT1、 SPAG1、SPATA5、STK3、STX11、STXBP6、SUSD2、SUV39H1、SYDE2、TACC3、TAGLN、T EAD1、TEAD4、TENT5B、TGM2、THBS1、TK1、TMEM139、TMEM160、TNFAIP3、TNFRSF12 A、TNNC1、TPM1、TPX2、TRIP13、TSPAN2、TTF2、TUBB6、TUFT1、TYMS、UAP1、UBE2C 、UGCG、UHRF1、VKORC1L1、WWC1、WWC2、YAP1、ZBED2、ZDHHC18、ZNF488、ZNF704;、 and Any 210 to 233 of the following genes in gene set (2): AASDH, ABCA1, ABCC5, ABI3BP, ABLIM3, ACADVL, ACOT11, ACOX2, ACSL5, ADAM28, AGL, AGPAT4, ALDH3A2, ANKRD12, ANKRD22, ANKRD29, ANKRD42, ANTXR2, APBB3, ARAP3, ARHGEF2, ASF1A, ATP7A, ATXN1, BCL11B, BHLHE41, BMF, CA2, CASP1, CBR3, CCNG2, CDC42EP4, CDK1, CEBPB, CELSR3, CLCN3, CLDN4, COL6A1, COL6A2, CPE, CRABP2, CROT, CSRNP2, CSTA, CTNNBIP1, CTSB, CTSK, CXXC5, CYP1B1, CYP27C1, DDR1, DEDD2, DHX32, DIAPH2, DSC2, DSG3, DUSP6, DYNC2LI1, ELN, EPS8L3, ERAP2, FAM102A, FAM117B, FAM83B, FAM89B, FERMT1, FKBP2, FOS, FTH1, FXYD3, GDPD1, GOLGA5, GOLPH3L, GPNMB, GPRC5C, GRB10, GSN, HAS3, HBP1, HDAC1, HDHD2, HEY1, HOXA5, IFI44, IGSF3, IGSF9, INTS3, IRAK2, IRF9, IRX5, ITGA2, KCNMA1, KCNMB3, KCNN4, KIFAP3, KLF10, KLF13, KLHL3, KLK11, KRCC1, KRIT1, KRTDAP, LMTK3, LRP10, LTBP4, LXN, LYPD3, MALL, MANSC1, MAPK13, MARCKSL1, MFSD1, MFSD5, MGST2, MGST3, MLLT11, MLPH, MMP13, MSX2, MTMR11, MTMR9, MTSS1, MYO1A, NAGK, NAPEPLD, NCOA3, NFIL3, NPAS2, NRIP1, OAS1, OAS2, OASL, OFD1, OSBPL7, OTUB2, OVOL1, PAG1, PAK1, PCDHB2, PCDHB9, PCGF3, PCMTD2, PERP, PHF21A, PIK3C2B, PIK3R1, PIK3R2, PIK3R3, PIP4P2, PJA2, PKIA, PLA2G4C, PNRC1, PPP1R11, PRRX2, PTPRE, PYGB,<h2 style=";text-align:left;direction:ltr">RAC2、RALGPS1、RAPGEFL1、RBM23、RBM45、RBM47、RBP1、REEP6、RGL2、RGS17、 RHOC、S100A14、SAMD9、SEC14L2、SECISBP2、SH3PXD2A、SH3TC1、SHROOM2、SL C14A1, SLC1A2, SLC30A9, SLC35C1, SLC37A2, SLC39A11, SLFN5, SLITRK6, SLK, SMOC1, SNCG, SP1, SPIRE2, SPRY4, SQSTM1, SRD5A3, SSPN, STMN3, STX1A, T BX3、TCF25、TDO2、TET2、TFF1、TLR3、TMC4、TMC7、TMEM140、TMEM144、TMEM45 B、TP53INP1、TP63、TPD52L1、TRAPPC6B、TRIB1、TRIB2、TRIM13、TRIM31、TRI M38、TRIOBP、TRIP11、TSC22D1、TSPAN1、TTC17、TTLL3、TUBB3、UBC、ULK1、VA MP8、VGF、VPS52、VSNL1、WDR13、ZCWPW1、ZNF292、ZNF467、ZNF75D、ZSWIM7。、 2. The use according to claim 1, wherein the gene set comprises 430, 431, 432, 433, 434, 436, 437 or 482 genes.
3. The use according to claim 1 or 2, wherein the cancer is a cancer comprising a solid tumor.
4. The method of claim 3, wherein the solid tumor is in the lung, colon, ovary, cervix, uterus, peritoneum, testis, penis, tongue, lymph node, pancreas, bone, breast, prostate, soft tissue, connective tissue, kidney, liver, brain, thyroid or skin.
5. The method of claim 1 , wherein the cancer is selected from the group consisting of adrenocortical carcinoma, urothelial carcinoma of the bladder, invasive breast cancer, cervical squamous cell carcinoma and cervical adenocarcinoma, bile duct carcinoma, consensus molecular classification 1 of colorectal cancer, consensus molecular classification 2 of colorectal cancer, consensus molecular classification 3 of colorectal cancer, consensus molecular classification 4 of colorectal cancer, colon adenocarcinoma, lymphoid neoplasms diffuse large B-cell lymphoma, esophageal cancer, glioblastoma multiforme, squamous cell carcinoma of the head and neck, clear cell renal carcinoma, papillary renal cell carcinoma, low-grade glioma of the brain, hepatocellular carcinoma, lung adenocarcinoma, squamous cell carcinoma of the lung, mesothelioma, ovarian serous cystadenocarcinoma, pancreatic adenocarcinoma, pheochromocytoma and paraganglioma, prostate adenocarcinoma, rectal adenocarcinoma, sarcoma, skin melanoma, gastric adenocarcinoma, testicular germ cell tumor, thyroid cancer, thymoma, endometrial carcinoma and uterine carcinosarcoma.
6. The use according to any one of claims 1 to 5, comprising: a) measuring the expression level of a gene in a transcriptome obtained from said biological sample, b) for each gene of the gene set, converting the expression level of the gene obtained in step a) into a fractional rank by dividing the rank of the gene by the number of genes from the transcriptome, c) separating the score ranks obtained for the genes of gene set (1) from the score ranks obtained in step b) and calculating their average score rank (MFR-positive), d) separating the score ranks obtained for the genes of gene set (2) from the score ranks obtained in step b) and calculating their average score rank (MFR-negative), and e) Calculate the dgR score as MFR-positive-MFR-negative; or a) measuring the expression level of each gene of the gene set in the biological sample, b) for each gene of the gene set, converting the expression level of the gene obtained in step a) into a fractional rank by dividing the rank of the gene by the number of genes from the gene set, c) separating the score ranks obtained for the genes of gene set (1) from the score ranks obtained in step b) and calculating their average score rank (MFR-positive), d) separating the score ranks obtained for the genes of gene set (2) from the score ranks obtained in step b) and calculating their average score rank (MFR-negative), and e) calculating the deR score as MFR-positive-MFR-negative; wherein when the dgR or the deR score is greater than about 0.055, then the cancer is TEAD-active, and when the dgR or deR score is less than or equal to about 0.055, then the cancer is TEAD-inactive.
7. Use of a transcriptional signature for characterizing TEAD activity of a cancer in a subject in need thereof, wherein the transcriptional signature is obtained by measuring the expression levels of genes of a gene set in a biological sample of a tumor of the cancer, wherein the gene set is selected from set a) to mmmm) of Table 1.
8. The use according to claim 7, wherein when the cancer is - adrenocortical carcinoma (ACC) tumor, the gene set of the transcriptional signature is gene set a) or b); - bladder urothelial carcinoma (BLCA) tumor, the gene set of the transcriptional signature is gene set c); -invasive breast cancer (BRCA) tumor, the gene set of the transcriptional signature is gene set d); -BRCA basal tumor, the gene set of the transcriptional signature is gene set e) or f); -When the tumor is a non-BRCA basal tumor, the gene set of the transcriptional signature is gene set g) or h); -cervical squamous cell carcinoma or cervical adenocarcinoma (CESC) tumor, the gene set of the transcriptional signature is gene set i); -cholangiocarcinoma (CHOL) tumor, the gene set of the transcriptional signature is gene set j) or k); -colon adenocarcinoma (COAD) tumor, the gene set of the transcriptional signature is gene set 1); -COAD CMS1 tumor, the gene set of the transcriptional signature is gene set m) or n); -COAD CMS2 tumor, the gene set of the transcriptional signature is gene set o) or p); -COAD CMS4 tumor, the gene set of the transcriptional signature is gene set q) or q1); - lymphoid neoplasm diffuse large B-cell lymphoma (DLBC) tumor, the gene set of the transcriptional signature is gene set r) or s); -esophageal cancer (ESCA) tumor, the gene set of the transcriptional signature is gene set t) or u); - When the tumor is a glioblastoma multiforme (GBM), the gene set of the transcriptional signature is gene set v) or w); -head or neck squamous cell carcinoma (HNSC) tumor, then the gene set of the transcriptional signature is gene set x); -renal chromophobe cell carcinoma (KICH) tumor, the gene set of the transcriptional signature is gene set y) or z); -renal clear cell carcinoma (KIRC) tumor, the gene set of the transcriptional signature is gene set aa); -kidney papillary cell carcinoma (KIRP) tumor, the gene set of the transcriptional signature is gene set bb) or cc); - When the tumor is a low-grade glioma (LGG) tumor, the gene set of the transcriptional signature is gene set dd) or ee); -hepatocellular carcinoma (LIHC) tumor, then the gene set of the transcriptional signature is the gene set ff); -LIHC S1 tumor, the gene set of the transcriptional signature is gene set gg) or hh); -LIHC S2 tumor, the gene set of the transcriptional signature is gene set ii) or jj); -LIHC S3 tumor, the gene set of the transcriptional signature is gene set kk) or ll); - lung adenocarcinoma (LUAD) tumor, the gene set of the transcriptional signature is the gene set mm); -LUAD proximal inflammatory tumor, the gene set of the transcriptional signature is gene set nn) or oo); -LUAD proximal proliferative tumor, the gene set of the transcriptional signature is gene set pp) or qq); - lung squamous cell carcinoma (LUSC) tumor, the gene set of the transcriptional signature is gene set rr); -LUSC basal tumor, the gene set of the transcriptional signature is gene set ss) or tt); -LUSC classic tumor, the gene set of the transcriptional signature is gene set uu); -LUSC primary tumor, the gene set of the transcriptional signature is gene set vv) or ww); -LUSC secretory tumor, the gene set of the transcriptional signature is gene set xx) or yy); -Malignant mesothelioma (MESO) tumor, the gene set of the transcriptional signature is gene set zz) or aaa); -Ovarian serous cystadenocarcinoma (OV) tumor, the gene set of the transcriptional signature is gene set bbb); -OV differentiated tumor, the gene set of the transcriptional signature is the gene set ccc) or ddd); -OV immunoreactive tumor, the gene set of the transcriptional signature is gene set eee) or fff); -OV mesenchymal tumor, the gene set of the transcriptional signature is the gene set ggg) or hhh); -OV proliferative tumor, the gene set of the transcriptional signature is gene set iii) or jjj); - pancreatic adenocarcinoma (PAAD) tumor, the gene set of the transcriptional signature is gene set kkk) or kkk1); -rectal adenocarcinoma (READ) tumor, the gene set of the transcriptional signature is gene set lll); -READ CMS1 tumor, then the gene set of the transcriptional signature is the gene set mmm); -READ CMS2 tumor, the gene set of the transcriptional signature is gene set nnn) or ooo); -READ CMS4 tumor, the gene set of the transcriptional signature is the gene set ppp) or ppp1); -When reading an unclassifiable tumor, the gene set of the transcription tag is gene set qqq) or qqq1); -When reading a sarcoma (SARC) tumor, the gene set of the transcription tag is gene set rrr); -When reading a skin cutaneous melanoma (SKCM) tumor, the gene set of the transcription tag is gene set sss); -When reading a SKCM immuno-oncology, the gene set of the transcription tag is gene set ttt); -When reading a SKCM keratin tumor, the gene set of the transcription tag is gene set uuu) or vvv); -When reading a SKCM MITF low-expression tumor, the gene set of the transcription tag is gene set www) or xxx); -When reading a stomach adenocarcinoma (STAD) tumor, the gene set of the transcription tag is gene set yyy); -When reading a STAD MSI tumor, the gene set of the transcription tag is gene set zzz) or aaaa); -When reading a STAD MSS_EMT tumor, the gene set of the transcription tag is gene set bbbb) or cccc); -When reading a STAD MSS_TP53- tumor, the gene set of the transcription tag is gene set dddd) or eeee); -When reading a STAD MSS_TP53+ tumor, the gene set of the transcription tag is gene set ffff) or gggg); -When reading a testicular germ cell tumor (TGCT) tumor, the gene set of the transcription tag is gene set hhhh) or iiii); -When reading a thymus carcinoma (THYM) tumor, the gene set of the transcription tag is gene set jjjj); -When reading an endometrial carcinoma (UCEC) tumor, the gene set of the transcription tag is gene set kkkk); and -When reading a uterine carcinosarcoma (UCS) tumor, the gene set of the transcription tag is gene set llll) or mmmm).
9. The use according to claim 7 or 8, comprising: a) Measure the expression level of each gene of the gene set according to claim 1 or 2 in the biological sample, b) For each gene in the gene set shown in Table 1, divide the rank of the gene by the number of genes in the gene set according to claim 1 or 2 to convert the expression level of the gene obtained in step a) into a fractional rank, c) Multiply each fractional rank obtained in step b) by the coefficient associated with each gene in the gene set in Table 1 to obtain the product of each gene, the coefficients and gene sets of the genes are shown in Table 2; d) Sum the products obtained in step c) to obtain a discriminant score (S); e) For the gene set of Table 1, compare the discriminant score (S) obtained in step d) with the centroids of the TEAD activity (A) and TEAD inactivity (I) groups shown in Table 2; f) Determine whether (S) is closer to (A) rather than (I) according to the formula max(S,A)-min(S,A)<max(S,I)-min(S,I); and g) If (S) is closer to (A) rather than (I), then characterize the sample as TEAD-active.
10. The use according to claim 7 or 8, wherein The cancer is selected from the group consisting of adrenocortical carcinoma (ACC) tumors; bladder urothelial carcinoma (BLCA) tumors; invasive breast cancer (BRCA) tumors; BRCA basal tumors; BRCA non-basal tumors; cervical squamous cell carcinoma and cervical adenocarcinoma (CESC) tumors; bile duct carcinoma (CHOL) tumors; colon adenocarcinoma (COAD) tumors; COAD CMS1 tumors; COAD CMS4 tumors; lymphoid neoplasms diffuse large B-cell lymphoma (DLBC) tumors; esophageal carcinoma (ESCA) tumors; glioblastoma multiforme (GBM) tumors; head and neck squamous cell carcinoma (HNSC) tumors; kidney chromophobe carcinoma (KICH) tumors; kidney clear cell carcinoma (KIRC) tumors; kidney papillary cell carcinoma (KIRP) tumors; brain low-grade glioma (LGG) tumors; hepatocellular carcinoma (LIHC) tumors; LIHC S1 tumors; LIHCS2 tumors; LIHC S3 tumors; lung adenocarcinoma (LUAD) tumors; lung squamous cell carcinoma (LUSC) tumors; LUSC basal tumors; LUSC classical tumors; LUSC primary tumors; LUSC secretory tumors; malignant mesothelioma (MESO) tumors; pancreatic adenocarcinoma (PAAD) tumors; rectal adenocarcinoma (READ) tumors; READ CMS1 tumors; READ CMS2 tumors; READ CMS4 tumors; sarcoma (SARC) tumors; cutaneous melanoma (SKCM) tumors; SKCM immune tumors; SKCM keratin tumors; STAD MSI tumors; STAD MSS_EMT tumors; testicular germ cell tumor (TGCT) tumors; endometrial carcinoma (UCEC) tumors; uterine carcinosarcoma (UCS) tumors, and The uses include: a) Measure the expression level of each gene in the gene set related to the tumor in the biological sample, where the gene set is selected from set a), set c), set d), set e), set g), set i), set j), set l), set m), set q), set r), t), set v), set x), set y), set aa), set bb), set dd), set ff), set gg), set ii), set kk), set mm), set rr), set ss), set uu), set vv), set xx), set zz), set kkk), set lll), set mmm), set nnn), set ppp), set rrr), set sss), set ttt), set uuu), set zzz), set bbbb), set hhhh), set kkkk) and set llll) in Table 1; b) For each gene in the gene set, convert the expression level of the gene obtained in step a) to a fractional rank by dividing the rank of the gene by the number of genes in the gene set; c) multiplying each score rank obtained in step b) by a coefficient associated with each gene of the gene set to obtain a product for each gene (P gene i ), the coefficients and gene sets of the genes are shown in Table 2; d) determining a discriminant score (DS) of the gene set, wherein the discriminant score (DS) is the product P gene set obtained in step c). i The sum of the constant coefficients for the gene sets shown in Table 2, e) For the gene set, compare the discriminant score (DS) obtained in step d) with the threshold related to the gene set to determine whether the cancer is TEAD-active or TEAD-inactive, and the threshold is shown in Table 3.
11. The use according to any one of claims 1 to 10, wherein the biological sample is a sample from blood, plasma, serum, cerebrospinal fluid (CSF), tissue, cells or a tumor biopsy.
12. The use according to any one of claims 1 to 11, for characterizing a subject as having a TEAD-active cancer or a TEAD-inactive cancer.
13. The use according to any one of claims 1 to 11, for predicting whether a subject will have a positive response to a TEAD pathway inhibitor.
14. The use according to claim 12 or 13, wherein a TEAD pathway inhibitor is administered to the subject if the subject is characterized as having a TEAD-active cancer, or if the subject is predicted to have a positive response to a TEAD pathway inhibitor.
15. A method for characterizing TEAD activity of a cancer in a subject in need thereof, the method using a biological sample of a tumor of the cancer and comprising at least the steps of: a) measuring the expression level of a gene in a transcriptome obtained from said biological sample, b) for each gene in the gene set according to claim 1 or 2, converting the gene expression level obtained in step a) into a fractional rank by dividing the rank of said gene by the number of genes from said transcriptome, c) separating the score ranks obtained for the genes of gene set (1) from the score ranks obtained in step b) and calculating their average score rank (MFR-positive), d) separating the score ranks obtained for the genes of gene set (2) from the score ranks obtained in step b) and calculating their average score rank (MFR-negative), and e) calculating the dgR score as MFR-positive-MFR-negative; or a) measuring the expression level of each gene of the gene set according to claim 1 or 2 in the biological sample, b) for each gene of the gene set according to claim 1 or 2, converting the gene expression level obtained in step a) into a fractional rank by dividing the rank of the gene by the number of genes from the gene set, c) separating the score ranks obtained for the genes of gene set (1) from the score ranks obtained in step b) and calculating their average score rank (MFR-positive), d) separating the scores obtained for the genes of gene set (2) from the scores obtained in step b) and calculating their average score (MFR-negative), e) calculating the deR score as MFR-positive-MFR-negative; Wherein when the dgR or the deR score is greater than about 0.055, then the cancer is TEAD-active, and when the dgR or deR score is less than or equal to about 0.055, then the cancer is TEAD-inactive.
16. A method for characterizing TEAD activity of a cancer in a subject in need thereof, the method using a biological sample of a tumor of the cancer and comprising at least the steps of: a) Measure the expression level of each gene in the gene set according to claim 1 or 2 in the biological sample, b) For each gene in the gene set shown in Table 1, by dividing the rank of the gene bythe number of genes in the gene set according to claim 1 or 2, convert the expression level of the gene obtained in step a) to a fractional rank, c) Multiply each fractional rank obtained in step b) by the coefficient related to each gene in the gene set in Table 1 to obtain the product of each gene, and the coefficient and gene set of the gene are shown in Table 2; d) Sum the products obtained in step c) to obtain the discriminant score (S); e) For the gene set in Table 1, compare the discriminant score (S) obtained in step d) with the centroids of the TEAD-active (A) and TEAD-inactive (I) groups shown in Table 2; f) Determine whether (S) is closer to (A) rather than (I) according to the formula max(S,A)-min(S,A)<max(S,I)-min(S,I); and g) If (S) is closer to (A) rather than (I), then characterize the cancer as TEAD-active.
17. A method for characterizing TEAD activity in a cancer in a subject in need thereof, wherein The cancer is selected from the group consisting of adrenocortical carcinoma (ACC) tumors; bladder urothelial carcinoma (BLCA) tumors; invasive breast cancer (BRCA) tumors; BRCA basal tumors; BRCA non-basal tumors; cervical squamous cell carcinoma and cervical adenocarcinoma (CESC) tumors; bile duct carcinoma (CHOL) tumors; colon adenocarcinoma (COAD) tumors; COAD CMS1 tumors; COAD CMS4 tumors; lymphoid neoplasms diffuse large B-cell lymphoma (DLBC) tumors; esophageal carcinoma (ESCA) tumors; glioblastoma multiforme (GBM) tumors; head and neck squamous cell carcinoma (HNSC) tumors; kidney chromophobe carcinoma (KICH) tumors; kidney clear cell carcinoma (KIRC) tumors; kidney papillary cell carcinoma (KIRP) tumors; brain low-grade glioma (LGG) tumors; hepatocellular carcinoma (LIHC) tumors; LIHC S1 tumors; LIHCS2 tumors; LIHC S3 tumors; lung adenocarcinoma (LUAD) tumors; lung squamous cell carcinoma (LUSC) tumors; LUSC basal tumors; LUSC classical tumors; LUSC primary tumors; LUSC secretory tumors; malignant mesothelioma (MESO) tumors; pancreatic adenocarcinoma (PAAD) tumors; rectal adenocarcinoma (READ) tumors; READ CMS1 tumors; READ CMS2 tumors; READ CMS4 tumors; sarcoma (SARC) tumors; cutaneous melanoma (SKCM) tumors; SKCM immune tumors; SKCM keratin tumors; STAD MSI tumors; STAD MSS_EMT tumors; testicular germ cell tumor (TGCT) tumors; endometrial carcinoma (UCEC) tumors; and uterine carcinosarcoma (UCS) tumors, and The method uses a biological sample of a tumor of the cancer, and The method comprises at least the following steps: a) measuring the expression level of each gene in a gene set associated with the tumor in the biological sample, wherein the gene set is selected from the group consisting of set a), set c), set d), set e), set g), set i), set j), set l), set m), set q), set r), set t), set v), set x), set y), set aa), set bb), set dd), set ff), set gg), set ii), set kk), set mm), set rr), set ss), set uu), set vv), set xx), set zz), set kkk), set lll), set mmm), set nnn), set ppp), set rrr), set sss), set ttt), set uuu), set zzz), set bbbb), set hhhh), set kkkk) and set llll); b) for each gene in the gene set, converting the expression level of the gene into a fractional rank by dividing the rank of the gene by the gene weight of the gene in the gene set; c) multiplying each score rank obtained in step b) by a coefficient associated with each gene of the gene set to obtain a product for each gene (P gene i ), the coefficients and gene sets of the genes are shown in Table 2; d) determining a discriminant score (DS) of the gene set, wherein the discriminant score (DS) is the product P gene set obtained in step c). i The sum plus the constant coefficient for the gene set shown in Table 2; e) for the gene set, comparing the discriminant score (DS) obtained in step d) with a threshold associated with the gene set to determine whether the cancer is TEAD-active or TEAD-inactive, the threshold being shown in Table 3.
18. A kit comprising a solid support comprising a set of nucleic acids for determining transcription of a gene set according to claim 1, 2 or 7.
